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ABSTRACT, - 
The work presented-in this thesis deals with a study of 
vitamin A and related factors in two groups of cancer patients 
.*.; - with additional studies on experimental animals. Twenty 
patients with newly diagnosed, histologically proven lung cancer 
and nineteen patients with advanced testicular teratoma, many of 
whom had metastases in the lungs were selected for study. 
The patients with lung cancer had significantly lower 
concentration of vitamin A in the serum than in the controls, and. 
these low levels were related to low levels of retinol-binding 
protein (RBP), the carrier protein for vitamin A. ' In addition, 
subnormal serum zinc levels which were positively correlated with 
both vitamin A and RBP were also observed in these patients. These 
results are suggestive of a role for zinc in the vitamin A 
metabolism of these patients. 
The effect of corticosteroids as a factor in affecting plasma 
vitamin A was investigated in healthy male Wistar-Albino rats. 
Corticosteroid treatment reduced the weight of the thymus and caused 
a loss' of vitamin A. Concomitant administration of vitamin A did 
not significantly increase the size of the gland, but giving 
vitamin A increased its vitamin A content above that found in control 
animals. The thymus plays an important role in cell-mediated and 
other immune reactions. The significance of these observations 
with respect to depressed cell-mediated immunity in patients with 
cancer, and particularly lung cancer, has been discussed. 
Studies on the vitamin A status of patients with metastatic 
testicular teratoma suggested-that decreased synthesis of its 
carrier proteins, RBP and prealbumin were responsible for the 
lower vitamin A levels when compared to age-matched healthy-male', 
subjects. - During each course of. treatment with vinblastine andý 
bleomycin, or cis-diamine dichloroplatinum (II) together with the 
above drugs, the blood levels of vitamin A and the status with 
respect to water-soluble vitamins, thiamineý, and pyridoxine-showed, 
a marked fall., However, the overall effect from the beginning of 
the first course toýthe beginning of the fourth course was thaý. 
blood, levels of vitamin A were significantly higher at, the end of 
treatment, whereas the status with respect to water-soluble vitamins 
remained the same or deteriorated further. 'The difference between 
the effects on vitamin A and water-soluble, vitamins, thiamine and 
pyridoxine can be explained by the fact that blood levels of vitamin A 
are affected by liver function-and-this may have improved, during 
treatment,, whereas the status withýrespecý-to thiamine and-pyridoxine 
i!, dep. --ndent on dietary intake., 
The adverse nutritional side effects of, chemotherapy, were also 
observed in, healthy male Wistar-Albino. rats. Treatment with 
vitamin A prior to administration of vinblastine reduced some of these 
side effects. The potential role of vitamin A-as an adjuvant to 
chemotherapy has also been discussed., 
ACKNOWLEDGMENTS 
I wish to express my deep gratitude to Prof. J. W. T. Dickerson 
and to Dr. T. K. Basu for their. advice, guidance, and encouragement 
during my period of training. 
My thanks are also due to Drs. D. Donaldson and S. Sakula of , 
the Redhill General Hospital, East Surrey, and to Dr. T. J. McElwain 
and his staff at the'Royal Marsden Hospital, Sutton, Surrey, for 
allowing me to study the patients under their care. and for their 
help in the collection of blood samples. I am also thankful to 
Mr. P. Scorbie-Trumper and the staff of the University Animal Unit 
for their assistance in caring for my animals. 
am very grateful to the Commonwealth Tropical Medicine 
Research Awards Scheme for financial support, an, 0 to the Faculty of 
Medicine, University of Sri Lanka fur granting me overseas s-cudy- leave. 
My sincere thanks also go out to Mrs. Megan Evans for typing and 
improving the presentation of this thesis. 
I amAndebted to my parents for looking after my daughter during 
my stay abroad, and last, but not least, to my husband for his help, 
encouragement and cheerful optimism at all times. 
CONTENTS 
Page 
CHAPTER ONE 
GENERAL INTRODUCTION I. 
1.1. Nutrition in relation to cancer 2 
1.2. Vitamin A 4 
1.2.1. Structure and metabolism 4 
1.2.2. Deficiency, excess and the possible 10 
mode of action 
1.3. Vitamin'A and. cancer in experimental animals 13 
1 '3.1. Vitamin A deficiency and chemical 13 
carcinogenesis 
1.3.2. Prevention of cancer by vitamin A 13 
and its derivatives (retinoids) 
1.3.3. Synthetic retinoids and cancer 15 
prevention 
1. *3.4. Possible mode of action of retin'. oids . 
18 
1.4. Vitamin A and cancer in man 19 
1.5. Cancer 21 
1.5.1. Lung cancer 21 
1.5.2. Testicular teratoma Metastatic 27 
lung cancer 
1.6. Nutritional problems of the cancer patient 30 
1.7. Treatment of cancer and its effect on 33 
nutrition 
1.7.1. Treatmentýof lung cancer 33 
1.7.2. Treatment of testicular teratoma 35 
1.7.3. Drugs used in chemotherapy 37 
Page 
1.7-4. Cell cycle and combination 43 
chemotherapy 
1.7.5. Adverse effects of chemotherapy 46 
1.8 Nutritional problems associated with 48 
chemotherapy of cancer 
1.9 Conclusion and plan of present studies 51 
CHAPTER TWO 
VITAMIN A AND LUNG CANCER IWMAN 54 
2.1. - Introduction 55 
2.2. Patients 57 
2.3. Analytical-methods' 62 
2.3.1. Determination of vitamins A and E 62 
in the serum 
, >< 
2.3-2. Determination of serum-s-carotenelý 63 
2.3.3. Determination of retinol-binding 66 
protein in the'serum, 
2.3.4. Determination of prealbumin, in 66 
the serum 
2.3.5. Determination of proteins in the 71 
serum 
2.3.6. Determination of 11-hydroxy 71 
corticosteroid-levels in the serum 
2.3.7. Determination of zinc and copper 73 
'in the serum 
2.4. Results 76 
2.5. Discussi on 88 
Paqe 
CHAPTER THREE 
EFFECT OF CORTICOSTERONE ON THE VITAMIN A 94 
STATUS OF RATS 
3.1. Introduction 95 
3.2. Experimental protocol 97 
3.2.1. . Effect of co, , rtic'os'te'r6'ne treatment. 97 
for different intervals of time 
3.2.2. ' Effect of treatment with 97 
corticosterone and retinol for 
one week 
3.3. Analytical me thods 99 
3.3.1. DeterminatiOn'Of vitamin A 99 
in tissues 
3.4. Results 101 
3.4.1. Effect of corticosterone treatment 101 
for different intervals of time 
3.4.2. Effect of treatment with 104 
corticosteron'e and retinol for 
one week 
3. ý. Discussion 110 
CHAPTER FOUR 
VITAMIN A AND METASTATIC TESTICULAR TERATOMA 113 
IN MAN 
4.1. - Introduction 
114 
4.2. Patients 116 
Page 
4.3. Analytical methods 123ý 
4.3.1. 'Determination of plasma ascorbic 123 
acid 
4.3.2. Determination of-transketolase 123 
stimulation 
4.3.3. Determination of transaminaseý 125 
stimulation 
4.4. Results 130 
4.4.1. Pre - -treat I mentýýalues- 
130 
4.4.2(a) Effect of chemotherapy 135 
(Samuels *regimen)-t r ", -,, 
4.4.2(b) Effect of chemotheýapy- 149 
(Einhorn regimen) 
4.5. Discussi dn- 163 
CHAPTER FIVE 
EFFECT OF BLEOMYCIN AND VINBLASTINE ON NOPMAL. 1169 
HEALTHY MALE RATS 
5 vl. Introduction 170 
171 5.2. Eýperimental protocol 
5.2.1. Effect of bleomycin 171 
5.2.2. Effect of vinblastine 171 
5.2.3. Effect of vinblastine in 172 
combination with bleomycin 
5.2.4. Effect of vitamin A supplements 173 
on vinblastine treatment 
5.2.5. Effect of Vitamin A and zinc 
sulphate supplementation on 
vinblastine treatment 
5.3.. Analytic al methods 
5.3.1. Determination of zin c in the liver 
5.4. Results 
5.4.1.. Effect of bleomycin 
5.4.2. Effect of vinblastine 
5.4.3. Effect of vinblastine in 
combination with bleomycin 
5.4.4. Effect of vitamin A supplements 
on vinblastine treatment 
5.4.5. Effect of vitamin A and zinc 
sulphate supplementation on 
vinblastine treatment 
5.5. Disrussion 
CHAPTER SIX 
GENERAL DISCUSSION 
REFERENCES 
Page 
173 
175 
175 
177 
177 
179 
182 
187 
190 
194 
197 
212 
I 
1 
CHAPTER ONE 
GENERAL INTRODUCTION 
2 
1.1 NUTRITION IN RELATION TO CANCER 
Nutrition has long been'tho'ught to affect the pathogenesis of 
several cancers in-man. Epidemiological evidence suggests that 
50 - 90% of all cancers are of environmental origin (Ackermann, 
1972; Rubin, 1973), and are therefore potentially preventable 
(Alcantara and Speckmann, 1976). Environmental poll6tion, radiation, 
excessive use of tobacco and food additives contribute to a small, 
extent to the development of neoplasms. It*is'evident however, 
that a large percentage of ýertain cancers are related to nutritional 
factors. A current estimate points to the fact that 50% of a. 11 
cancers in women and a third of all cancers in men are causatively 
related to nutritional factors (Wynder, 1976). 
The relationship between diet,, nutrition aI nd cancer is very 
compl ex. Nutritional deficiencies, excesses or imbalances, may 
affect the development and progre'ssion of the cancer. ' 
As early as 1914, Rous obs*e:, ved that týe eevelopment of mammary 
tumours and metastases was delayed by food 'restriction. An a later 
study, Tannenbaum and Silverstone (1953) showed that many diverse 
types of neoplasms, spontaneous and chemically induced, respond to 
caloric deprivation by a reduction in tumour incidence and a delay 
in the appearance of the tumOur. Lea (1966) showed a relationship 
between excessive fat consumption and deaths from certain types of 
cancer in man. Excessive intake of fat is associated with increased 
incidence of cancer of the breast and endometrium (Wynder et al., 1966). 
In experimental animals, carCinogenesis, particularly in the liver, 
could be modified through a change in the proportion or composition 
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of the dietary protein (Tannenbaum and Silverstone, 1953)., It 
has been suggested that the fibr'e'cofitent-'of the'diet May eýert 
a protective effect against th e development of, cancer of theýlarge 
bowel (Burkitt, 19 71ý. 
Deficiencies or excesses of-seveýal inorganic substances are - 
also implicated in the genesis of -tumodrs. For example, iodine 
deficiency may account for a relatively high rate of cancer of the 
thyroid in areas where goitre is endemic (Cowdry, 1968). A long 
standing deficiency of iron, as in the'Plummer-Vinson syndrome is 
associated with cancer of 'the upýer alimentary'tract in man' 
(Laarson et Al. s' 1975) ' 'I n'e'xperi mental animals, dietary"zinc 
deficiency has been shown tO'inhibit the"development Of Walker - 256 
carcinosarcoma and LeWis lung carcinoma, 'despite onlý small' differences 
with weight-matched controls (De Wys and Pories3,1972). 
A high correlation has been observed between alcohol consumption 
and cancer of the oral cavity, pariicularlyý the mouth, larynx and 
oesophagUs (Wynder et- al. 1957). ' 'Clinical -obse'rvati on's Shoý "chronic 
alcoholism to be often associated with' deficiencies ofB vitamins 
(Vitale, 1971). The derivatives of*riboflavin, aB vitamin, play an 
integral role in the respiratory system. - Significant hyperplasia 
has been observed 'in the skin of riboflavioeficient mice. 
Moreover, riboflavin deficiency enhances the susceptibility of mouse 
skin to tumour yield when treated with carcinogen 'and promoter as 
comPared to control treatment (Wynder and Chan, "1970). 
The association between vitamin A and cancer of' epithelial 
tissues is perhaps the most exciting. About 80% of the cancers that 
4 
afflict man are of epithelial origin (Cairns, 1975). Vitamin A 
plays an important role in controlling the differentiation of. 
epithelial tissues (Moore, 1967). Early studies in experimental 
animals revealed that vitamin A deficiency leads to metaplastic 
changes in epithelip, particularly in the respiratory, 
gastrointestinal and urogenital tracts (Wolbach and Howe, 1925). 
These metaplastic changes may be considered the'firststep in the 
transformation from a normal to aneoplastic tissue. 
Furthermore, there is increasing epidemiological evidence 
pointing to an association between vitamin A and cancer of epithelial 
tissues, particularly the"lung, in man. (Bielke, 1975; Mettliý et al., 1979)' 
Therefore, it is not surprising that'a great deal of interest is 
focussed on-the relationship of vitamin A to cancer of epithelial 
tissues. 
VITAMIN A 
1.2.1. Structure and metabolism of Vitamin A. 
Vitamin A is a fat-soluble vitamin which exerts a number of 
important biological effects. It is necessary for vision (Wald, 1968), 
growth, reproduction (Thompson et al., 1964) and proper differentiation 
of epithelial tissues (De Luca and'Wolf, 1968; Wong a nd Buck, 1971; 
Olson, 1972). The biologically, active form in mammalian tissues is 
all trans-retinol (fig. 1-1). Its oxidized form retinal is involved 
in the visual cycle (Wald, 1968). Retinal can be further oxidised 
irreversibly to retinoic acid which is capable of promoting growth 
and differentiation of'epithelial tissues, but is not active in vision 
(Dowling and Wald, 1960) and reproduction (Thompson et al., 1964). 
The sources of vitamin A in the diet include retinyl esters 
from animal sources or its precursor $-carotene from plants. It 
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is absorbed'from the upper intestine in the micellar form, aný is 
transported to theliver mainly via the lymphatic pathway in. 
association with chylomicrons (Huang and Goodman, 1965; Goodman et 
al., 1966).. The chylomicron vitamin Vis removed from the 
circulation by the liver (Goodman et al., 1965) where it is 
rnost 
re-esterified and stored mainly as the palmitate. Urilike other h 
vitamins, a fairly large amount of vitamin A is stored in the body, 
mainly in the liver. 
Retinol may also be conjugated with UDP glucuronic acid in the 
liver to form glucuronides or may be oxidised to retinal and, finally 
to retinoic acid. Retinoic acid, also forms a glucuronide in the 
liver and these glucuronides, together with perhaps a small amount 
of free retinoic acid are excreted efficiently into the bile,. 
(Zachmann et al., 1966). Glucuronides of the bile are_partially 
reabsorbed into the gut and transported again to the. li ver,, thereby 
giving an enterohepatic circulation. Most of the biliary 
alururonides however, seem to be hydrolyzed in the gut by enteric 
bacteria and excreted in the faeces as a mixture of free retinoic 
acid, possibly free retinol, the intact glucuronides and-some, 
'other 
unidentified products (Olsons 1968). Metabolites of vitamin A are 
predominantly excreted via the faeces. Kidney also excretes an 
appreciable amount of vitamin A metabolites. such as retinoyl_ 
glucuronides, but these compounds, have not been well characterized 
(Nath and Olson, 1967; Sundaresan and Sundaresan,. 1975). 
The oxidised form of vitamin A, retinoic acid is not stored in .- 
the body (Dowling and Wald, 1960) and is transported in the plasma 
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bound toýalbumin (Smith et, al'*,, -1973i., Vitamin'A is mobilised from- 
theflver as the-free alcohol, retinol's bound to a specific protein - 
retinol-binding protein - RBP (Kanai et al., 1968). This is the form 
in which vitamin A is transported from the liver to peripheral tissues 
such as the'eye', ' intestinal mucosa, gonads and salivary-glands'to" 
supply their metabolic needs'. ' It is likely that the delivery of ''' 
Vitamin-'A'to-tissues is controlled by processes which regulate the '' 
production'an'd secretion of RBP by the-liver (Goodman, 1974).. 
''Retinol-bin'ding protein is associated with the membrane 
components of'the liver cell,, -mainly the Golgi fraction and the 
endoplas6ic reticulum (Glover et al. *, 1974). Following its -synthesis in the 
ribosomes, ' . it is presumably transferred to the' endoplasmic reticular 
membrane where it can pick up retinol released from esters by the 
action of liver esterase. It is then released into the circulation 
as the ýholoprotein (Glover et-al. , 1974. The 'apoprotein'by' itself is much 
lessý'stable than the' holoprotein (Glover et al., '1974). 
-Retinol-binding protein is a relatively small molecular'weight 
protein, composed of -a single -polypeptide, chain with a molecular 
weight of approximately 21,000 daltons (Raz etal., 1970; Peterson, 
1971ý. 'It has a. al'-mobility on electrophoresis and appears'as three 
closely spaced bands on disc-gel electrophoresis, a'non-fluorescent 
comp6nent, corresponding to apo-RBP and two fluorescent bands 
corresponding to-holo-RBP. The difference in mobilities arises 
from'differences in the nett charge per unit density through thd loss 
of amide groups or a terminal aminoacid during isolation (Glover, _1973). 
RBP contains a high proportion of aromatic amino acids and 
9 
dicarboxylic acids, some of which may' exist as amides. It has a 
single-bi . nding site for a molecule of retinol (Kanafet al., 1968) 
and circulates mairfly as the holoprotein (Glover, 1973). 
.1 
Retinol-binding protein interacts strongly with prealbumin and 
circulates as a 1: 1- molar complex of molecular weight of approximately 
75,000 daltons in the plasma (Kanai et al., 1968; Raz et al.,. 1970 and 
Peterson, 1971q. The interaction of retinol with RBP appears to be 
stabiliSed by the formation of RBP-prealbumin complex. Moreover, 
the formation of the complex may prevent the excretion of retivol- 
bound RBP by the kidney (Vahlquist, 1972). The'formation of 
RBP-prealbumin complex is very sensitive to ionic strength with 
dissociation occurring at low ionic strength (Van Jaarsveld et al., 
1973). 
Pre-albumin is a tetrameric molecule, with a molecular weight 
of 54,000 daltons (Blake et al., 1971). Like RBP, prealbumin also 
contains a high proportion I of ýrom-:, Itic anino acids, particiul: irly . 
tryptophan (Goodman, 1974). Although RBP normally'circulates 
as a 1: 1 molar complex with prealbumin, there is evidence to 
suggest that prealbumin may contain four binding sites for RBP 
(Van Jaarsveld et al., 1973). Thus'it'. is Possible that each 
subunit contains a single binding site for RBP. 'In addition, 
prealbumin is'one of the three proteins involved in the transport 
of thyroid hormones in the plasma (Ingbar, 1963). Raz and Goodman- 
(1969) and Van Jaarsveld. et al., (1973) have shown that there-is no 
interdependence of the binding of thyroxine and of RBP to-prealbumin. 
Peterson and co-workers using isolated intestinal mucosal cells 
9. 
showed, that the cellular uptake of retinol is mediated by a receptor 
(Rask and Peterson, 
'1976). 
The mucosal cells readily accumulate 
labelled retinol from its complex with RBP without concomitant 
cellular uptake, of4the. protein itself. The membrane receptor. seks 
to recognize the protein rather than the retinol. During the uptake 
of retinol, an altered form of RBP is generated, which cannot bind 
retinol'and consequentl'y prealbumin. It differs from holo-RBP, in' 
that it lacks the terminal arginine residue (Rask et al. ', 1971). 
Heller-an'd Chen '(1977)"using 'Isolated Pigment epithelial cells from 
bo'Vine retina and labelled RBP also showed that the binding was at 
the I cell surface without penetration of RBP into the cell. 
Therefore, RBP is not only important for the transport of retinol 
in the blood, but is also, an indispensable entity for recognition by 
the target cells and consequently for penetration of retinol. through 
the plasma membrane. 
A cellular binding, prote4n which binds retinol-was first 
discovered by Bashor et. al... (1973). This protein has a stringent 
requirement for an alcohol group at C-15 and therefore does not 
bind retinal or_retinoic acid. - 
Later Ong and Chytil (1975) detected 
an, intra-cellular binding protein specific for retinoic acid. These 
binding proteins are now called cellular retinol-binding protein and 
cellular retinoic acid-binding protein respectively. Cellular 
retinol-binding protein is a protein distinct from plasma RBP both in'. 
its antigenic as well as its chemical properties. 
binding protein is widely distributed in the adult rat, (Bashor et all.,, 
1973; Ong and Chytil, 1975, and Bashor and Chytil, 1975). It is not 
present iq muscle and serum. It has been detected in man, rat, mouse 
Ad&. 
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rabbit, cow, sheep and chick (Chytil and Ong, 1978). Retinoic acid 
binding protein is also present in some tissues. It is conceivable 
that in any tissue where vitamin A is. known to control the differentiation 
of, epithelia, such binding proteins might exist, fulfilling similar, 
4 
if not identical functions. 
Deficiency, excess and the possible mode of action 
Very little is known about the mechanism of action of vitamin, A , 
except. for, its role in vision. Nevertheless, studies on vitamin A 
deficiency and excess have provided useful leads as to its function at 
the molecular level. Thompson and co-workers, (1964) showed that vitamin 
AJs necessary for-reproduction. Injury to the repro ductive organs, 
failure in reproduction and congenital malformations have been observed 
in vitamin A deficiency in experimental animals (Moore, 1967). 
However, the most profound effect of vitamin A is its ability to 
control the differentiation of epithelial tissues. In rats fed a 
vitamin A deficient diet, normal epithelium is replaced by stratified 
keratinizing epithelium in various parts of the respiratory tract, 
alimenzary tract, eyes and paraocular glands and the genito--urinary 
tract (Wolbach and Howe, 1925). Growth activity of the epithelium is 
not, diminished, but greatly augmented, suggesting the acýuisition of 
I 
peoplastic properties. Addition Of vitamin A caused a reversal of 
these changes (Wolbach and Howe, 1933). ' Epithelia of ectodermals 
CA mesodermal and endoermal origin are similarly affected. The replacement 
gardless of the original structure and function, is epithel. ium, re 
identical in all locations and is comparable in all its layers with the 
epidermis (Wolbach, 1954). An exception is the intestinal mucosa, 
where the number of mucus-secreting goblet cells is reduced considerably, 
but the epithelium does not keratinize (De Luca et al., 1969). 
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Vitamin A iý also involved in-the maintenance of mesenchymal 
structures (Fell and Mellanby, 1952; Fell and Dingle, 1963; Fell, ý1970). 
Deficiency of, vitamin A leads to defective bone modelling. Vitamin A 
deficiency also leads to degeneration of nerves and, ýhydrocephalus. 
(Moore, 1967). Also, numerous anatomical deformities may occur in the 
foetus as a result of lack of vitamin A in the maternal diet. 
Ingestion of excessive amounts of vitamin A is also harmful and may 
lead'to toxic side effects, such as headache, vomiting, diarrhoea. In 
hypervitaminosis A, mucous cell formation may occur in keratinizing, 
epithelium. Excess of vitamin A also has profound effects on cartilage 
and bone tissue inývivo (Kochhar and Aydelotte, 1974) or in organ culture 
(Fell and Mellanby,, 1952). Also, there is some evidence to suggest a 
teratological effect of excessive amounts of vitamin A in humans. Gal 
and co-workers (1972) observed elevated maternal serum vitamin A levels 
in some human central nervous system malformations. 
-- It1s now believed that some of the effects of hypervitaminosis A 
are due, to labilisation Of lysosomal membranes (Dingle and Lu cy, 1965). 
Recent work suggests that the toxic manifestations of hypervitaminosis A 
occur when excessive amounts of vitamin A are presented to the cell 
membrane in association with lipODroteins, rather than specifically', 
bound to RBP (Smith and Goodman, 1976). Thus RBP may not only regulate 
'the supply of retinol to the tissues, but also protect tissues from 
the surface active properties of the vitamin. Not only retinol or 
V, ý- so retinyl estersý retci'dnoic acid aa4a has undesirable side effects because A 
of its ability to damage lysosomal membranes (Goodman et al., 1974). 
Although retinoic acid has the ability to control the differentiation 
of'epithelial tissues, it cannot replace retinol in vision or- 
reproduction., The failure of retinoic acid to replace retinol in all 
- 
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its physiological functions seem to suggest that the effectsof retinol 
and'retinoic acid are not . mediated by a single common intemediate, "but 
that retinol and retinoic acid act as separate metabolic entities. 
This conclusion isjurther supported by the inability of cellular. 
retinol binding protein to bind retinoic acid (Bashor et al., 1973). 
Recently, De Luca and co-workers demonstrated the direct 
involvement of retinol and reinoic acid on the biosynthesis of glyco- 
proteins, which are important constituents of the cell membrane. The 
mode of action of retinol and retinoic acid in the biosynthesis of glyco- 
proteins has been reviewed elsewhere (De Luca, 1977). Howeverý the 
possible significance of this observation is still not clear. 
For a long time it has been speculated that the mechanism oUaction 
of vitamin A might be similar to that of steroid. hormones (Bashor et al., 
1973). They are: believed to act on their target cells by binding first 
to specific proteins called receptors in the cytosol. Each protein 
has a high affinity and specificity for its steroid molecule. The 
ligand-protein complex is then translocated to the nucleus, whereAt 
interacts with chromatin, changing the expression of the genome. - This 
interaction is manifested by alterations in nuclear RNA synthesis, 
resulting in changed differentiation. And indeed, altered nuclear RNA 
synthesis has been reported in vitamin A deficient and replete animals 
(Zachman, 1967; Zile and De Luca, 1970). 
It is still not certain whether the cellular retinol and retinoic 
ad Id proteins are the recepiors for vitamin A. However, Chytil and 
Ong (1978) have recently been successful in detecting specific 
interactions of the complex (3 H) retinol-cellular retinol-binding 
protein with nuclei isolated from livers of vitamin A deficient rats. 
No specifip binding of free (3 H) retinol was observed indicating'the 
necessity of cellular retinol-binding protein for the interaction to occur. 
13 
VITAMIN A AND CANCER IN 
EXPERIMENTAL ANIMALS 
1.3.1. Vitamin A deficiency and chemical carcinogenesis 
Vitamin A and its derivatives, collectively called retinoids, 
are important in controlling not only the normal differentiation 
of epithelial tissues, but also of premalignant epithelia (Moore, 
1967). In fact, vitamin A deficiency, at least in the experimental 
animal, enhances the susceptibility of tissues to chemical 
carcinog'enesis. Nettesheim and co-workers (1975) showed that low 
vitamin A intake increases the susceptibility of rats to develop 
lung tumours, on intra-tracheal instillation of 3-methyl cholanthrene. 
A similar effect has also been observed in the induction of car&inoma 
of the bladder by N-(4-(5-nitro, 2-furyl) ? --thiazolyl) furamide-FANFT 
(Cohen. 2t al., 1974). Also, greater incidence of colonic carcinoma 
in rats exposed to aflatoxin has been associated with low dietary 
and hepatic concentrations of vitamin A (Newberne and Rogers, 1973).. 
Harris and co-workers (1972) observed that both vitamin A 
defiCiency and multiple intra-tracheal instillation of benzo(a)py*rene 
oxide caused squamous metaplasia in the tracheal epithelium of the 
hamster. By light microscopy, the squamous metaplasia without cell 
atypia caused by vitamin A deficiency is morphologically similar to 
that caused by carcinogen administration. However, significant 
differences were observed at the ultrastructural level. 
Prevention of cancer by vitamin A derivatives (retinoids) 
It, is possible that vitamin A may prevent squamous mptaplasia 
and the. development of carcinomas which later arise from these 
precancerous changes. Chu and Malmgren (1965) observed that vitamin A 
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inhibits th6-inddction of tumours of the forestomach and cervix 
of the Syrian hamster by carcinogenic polycyclichydrocarbons. In 
a later study, Saffibtti et al. (1967), reported that treatment 
with high doses of retinyl palmitate markedly inhibited the 
induction of, tracheo-bronchial squamous metaplasia and squamous 
cell tumours by intrýa-tracheal instillation of benzo(a)pyrene oxide 
in the Syrian'hamster. Furthermore, vitamin A has also beeri shown 
to inhibit squamous metaplasia induced by benzo(a)pyrene in hamster 
trachea in-organ culture (Crocker and Sanders, 1970). Bollag (1971) 
also observed-a therapeutic effect of retinyl palmitate and of,. 
retinoic acid on-skin tumours induced by dimethyl benzanthracene and 
Croton oil. -ý. -Sha#erger 
(1971) in studies on mice using dimethyl 
benzanthracene-croton oil tumour promoting system confirmed the tumour 
inhibiting effect of vitamin A. 
However,, other workers did not observe a protective effect of ' 
vitamin A against the development of tumours (Levii and Polliack, 
1968;, Smith et al., *1975a). Tnis may be due to the inability to, 
achieve high blood levels of vitamin A on administration of large 
doses and to the toxic effect resulting from the deposition of large' 
amountsW vitamin A in, the liver. Retinoic acid which is not stored 
in theIiver (Dowling and Wald, 1960) and is transported by albumin 
(Smith et'al., 1973a)is not without its own undesirable side effects, 
parti'cularly because of its ability to damage lysosomal, membranes, - 
(Goodman et al., 1974). The need arises therefore. to synthesize a- 
retinoid molecule which has the desired anticancer properties of 
retinoids, but lacks the toxic properties that had previously limited 
its usefulness. , In fact, attempts are now being made to use synthetic 
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retinoids in the prevention of cancer (Sporn et al., 1976; Sporn, 1977; 
Bollag, 1977). 
Synthetic retinoids and cancer prevention 
The retinoid molecule could be modified either in the cyclohexenyl 
ring, the polar terminal group, or in the hydrocarbon side chain 
(fig 1.2. A) without changing its anticancer action. 
The first successful use of a synthetic retinoid was made by 
Bollag (1974). In the synthetic analogue used in this study,. the 
cyclohexenyl ring was replaced by an aromatic trimethyl-methoxy phenyl 
(TMMP) ring and the terminal polar group of retinoic acid was replaced 
by an ethyl ester (fig 1.23). The systemic administration of this 
compound resulted in a marked regression of carcinogen-induced skin 
papillomas and carcinomas in mice. It possesses a greater therapeutic 
ratio than retinoic acid, that is, a more favourable margin between the 
effective antitumour dose and the hypervitaminosis A producing-dose. 
The TMMII derivative where the polar terminal group is replaced by an 
ethyl amide group is also active in the prevention of papillomas and 
carcinomas of mice and slightly less toxic (Bollag, 1975). Furthermore, 
the TMMP analogue of retinoic acid and its ethyl ester are also_ 
directly active in controlling the differentiation of tracheal. 
epithelial cells in organ culture and cause reversal of keratinized 
squamous metaplastic lesions (Sporn et al., 1975). Another synthetic 
analogue, a-retinyl acetate, in which the double bond of the cyclohexene 
ring has been moved to the 4,5 position (fig 1.2. C) also showed activity 
comparable to its natural a-analogue in controlling differentiation 
(Clamon et al., 1974). 
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In retinyl methyl ether, the polar terminal group is replaced 
by an ether group (fig 1.2. D). This compound was found to be as 
potent as retinol or retinyl acetate in supporting growth in the 
rat (Isler, 1949). -Moreover, it is substantially less toxic than 
retinol or retinyl acetate on acute administration to the rat. In 
the rat, retinyl methyl ether shows a much greater ability. than 
retinyl acetate to prevent mammary cancer induced by 7,12 dimethyl 
benz(a)anthracene (Sporn, 1977). , It is possible that retinyl 
methyl ether may be cleaved to retinol in the body and be 
subsequently stored as esters in the liver., This factor may limit, 
its chronic administration (Sporn, 1977). 
Morton (1960) pointed out the importance of the side chain in 
the search for biologically active retinoids. Modification of the 
side chain is more difficult and very little progress has, been made 
along these lines. In a long term study, Port and co-workers (1975) 
evaluated the ability of a synthetic analogue, 13-cis retinoic acid 
(1-ig 1.2. E) in preventing respiratory cancer in hairisters. In hamsters 
treated with a relatively low intra-tracheal dose of benzo(a)pyrene 
ferric oxide with no further treatment, there was a ten percent 
incidence of respiratory squamous carcinoma or in-situ carcinoma. The 
incidence of carcinomas was drastically curtailed by placing the 
animals on a life-time weekly dosage of 3 mg of 13-cis retinoic acid 
after completion of carcinogen dosing. Treatment with higher doses 
resulted in total prevention of the development of carcinomas. 
Furthermore, the treatment with even the high dose of 13-cis retinoic 
acid, did not result in manifest toxicity in the hamster, an 
equivalent dose of either all-trans retinoic acid or retinol would have 
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Figure 1.2. Structures of some retinoids 
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resulted in severe toxicity. - Iý 
Sporn and co-woýkers-(1976) have suggested the introduction of- 
a fluorine or chlorine, atom, in-appropriate positions of the side-, 
chain'to obtain synthetic retinoids with increased biological activity 
and -I ess "toxi ci ty. 
1.3.4. Possible mode of action of retinoids-- 
The mechanism by which retinoids exert a protective effect 
against'insults'by carcinogens is not'known. Metabolic activation 
of these hydrocarbons is jenerally considered to be necessary for 
their carcinogenic activity (Miller, 1970). They are believed to 
be metabolised by microsomal mixed function oxidases through an 
epoxide intermediate (Hill and Shih, 1974). They suggested that 
vitamin A and other retinoids may be interfering with the activation 
of polycyclic hydrocarbons, by inhibiting microsomal mixed function 
oxidases. ' This-inhibition has been demonstrated in the liver and 
lung, tissues of mice and hamsters. 
Chopra and Wilkoff (1976) in studies-on-cultured mouse prostate 
tissues, showed that retinoic acid inhibited and reversed the effect 
of1both 3-methyl cholanthrene (MCA) and methyl h-nitroso guanidine 
(MNNG). - MCA is a carcinogen which requires activation, while MNNG 
does not require any metabolic activation (Marquardt et al., 1972). 
This, -implies that retinoic acid is acting at two different sites-ýin. 
altering the hyperplastic response produced by these'two carcinogens 
(Chopra and Wilkoff, 1976). 
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The-binding of carcinogen to DNA is believed to be necessary 
to, induce anaplasia (Brookes and Lawley, 1964). Genta and his 
collaborators (1974), in studies on hamster trachea in organculture. 
found that greater quantities of labelled benzo(a)pyrene was bound 
to DNA of vitamin A deficient hamsters. It is possible-that 
vitamin A exerts its anticarcinogenic effect by preventing-the 
binding, of, carcinogen to DNA. 
ThUs, it is clear that retinoids have the ability to-, prevent 
the development or progress of epithelial cancer in experimental 
animals., It seems pertinent therefore, to determine whether an 
analogous, situation exists in man. 
VITAMIN A AND CANCER IN MAN 
Deficiency of plasma vitamin A has been observed in cancer of 
some epithelial tissues such as the stomach (Abels et al., 1941)9 
cervix (Wynder, 1969), oro-pharynx (Ibrahim et al., 1978) and 
respiratory tract (Basu et al., 1976). 
Dijkstra (1963) in an investigation of 330 consecutive patients 
wiih*proven bronchial carcinoma, seen in the northern parts of 
Netherland suggested that those born in winter months have a greater 
chance of getting bronchial carcinoma than those born in the summer 
months. The foetus at birth has a low supply. of vitamin A and in 
winter months the level of vitamin. A in cow's milk is at its lowest. 
Dijkstra speculates that if the newborn infant is fed on cow's milk 
that is low in vitamin A, the, vitamin A level of the infant may remain 
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low at the critical period of active bronchial development. This 
may result-An squamous metaplasia which later predisposes the -I, -. 
individual, to develoý bronchial carci noma, when exposed to-further 
bronchial insults. 
In a survey ofAietary habits and cigarette smoking in 8278 
residents of Norway, Bjelke (1975) observed that dietary vitamin A 
intake is negatively associated with lung cancer at all levels of 
cigarette smoking., The negative association between dietary vitamin A 
intake and lung cancer is more clearly expressed in histologically 
proven bronchial carcinomas other than adenocarcinoma. - The index 
of vitamin A used in this study included only a measure of the 
consumption of foods such as vegetables (especially-carrots),, milk 
and eggs; Failure to obtain information about the consumption of 
vitamin pills and liver, a rich source of vitamin A, casts some doubt 
on the findings. - 
In-a very recent study (Mettlin et al., 1979), retrospe,; tive 
dietary and smoking data were gathered from 292 male patients with 
lung cancer and 801 control patients with non-respiratory, non-neoplastic 
diseases, and lung cancer patients had a lower computed index of 
vitamin A than controls. Furthermore, the relative risk of lung 
cancer was reduced with high vitamin A intake and the reduction was 
most evident in heavy smokers. 
Thus it would seem to be I of great importance to study the 
association between vitamin A and primary and metastatic lung cancer. 
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1.5. CANCER 
A cancer is characterised by a group of cells that are behaving 
in an abnormal manner, escaping from some, if not all, the normal 
mechanisms which control cellular growth and anatomical arrangement. 
The transformation of a normal cell into a cancer cell may be the 
result of a number of complex interactions. The cells of malignant 
tumours, unlike those of benign tumours, invade local tissues and 
spread via the lymphatics, blood stream and body cavities to form 
secondary tumours or metastases remote from the site of origin. 
Most patients with malignant disease die from the harmful effects of 
disseminated disease rather than from the primary-tumour itself. 
Lung cancer and testicular teratomas, which often metastasise 
to the lung in the early stages, will be discussed in detail. 
1.5.1. Lung cancer 
Lung cancer was a rare disease fifty years ago. Today, it is 
the most common cause of death from cancer in man (fig 1.3) and now 
accounts for 6% of all deaths. Lung cancer is more common in men 
than in women, but, its incidence is rapidly increasing in women too 
(fig 1.4). 
Aetiology 
Doll and co-workers- in a 20 year survey of about 30,000 British 
doctors concluded that smoking is an important factor in the production- 
of carcinoma of the lung (Doll, 1950; Doll and Hill, 1964; Doll and 
Peto, 1976). The ratio of the death rate among cigarette smokers to 
that among life long non-smokers of comparable age for men under70 years 
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was 2: 1 and for men over 70 years 1.5: 1. These ratios suggest that 
4YOOA SPAOkIrIj 
between a half and a third of all cigarette smokers will diehif the 
excess death rates are actually caused by smoking. Wynder and 
co-workers (1970) in a retrospective epidemiological investigation7of 
350 lung cancer patients confirmed the close association_between 
cigarette smoking and lung cancer, particularly of the'squamous and 
oat cell types. 
A similar association between lung cancer and cigarette smoking 
has also been observed in a retrospective study of 108 female lung 
cancer patients (Wynder, 1973). As women adopt smoking habits 
similar to those of men death rates from lung cancer continue to 
increase. However, smoking cigarettes with a low tar yield is 
expected to considerably decrease the incidence of lung cancer. 
Among cigarette smokers, smoking more than one pack a day, a 
longer history of smoking, earlier starting age, inhalation and 
smoking non-filter cigarettes wre significantly associated'witý 
greater morbidity ratios. Doll (19770 in a study of the observation 
of mortality rates suggests that, in the absence of smoking, the 
mortality from lung cancer in men might be reduced by 90 - 95%. 
The mode of action of cigarette smoke is not clear. Tobacco 
or cigarette smoke contains a high proportion of polynuclear aromatic' 
hydrocarbons, some of which have been shown to be potent carcinogens 
in experimental animals (Wynder et al., 1963). Two of the most 
important carcinogens found in cigarette smoke are benzo( a)pyrenp 
(3.9 t 0.3 jig in smoke from 100 cigarettes) and dibenzanthracene 
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(A vig in smoke from 100 cigarettes). Cigarette smoke also 0. 
contains co-carcinogens. Therefore the relation of lung cancer 
to cigarette smoke may represent the summation of a number of 
different substances, including carcinogens and co-carcinogens. 
- Another less important contributory factor to the development 
of lung neoplasms is atmospheric pollution. The combustion of 
coal releases carcinogenic agents such as benzo(a)pyrene and arsenic. 
Thus,, it has been observed that lung cancer is more common in urban 
areas than in, rural districts. Respiratory tract cancers, are also 
common, in workers in asbestos industry, presumably as a result of 
local irritation. 
_The polynuclear aromatic 
hydrocarbons present in cigarette 
smoke are broken down by the enzyme aryl hydrocarbon hydroxylase to 
carcinogenic epoxides (Emery et al., 1978; Korsgaard and Trell, 1978). 
Not all smokers get lung cancer. It is possible that certain 
individuals are constitutionally predisposed to the disease if they 
smoke. The inducibility of aryl. hydrocarbon hydroxylase in peripheral 
blood lymphocytes of patients with squamous cell carcinoma of the lung 
was, significantly higher when compared to controls matched for age, 
social class and, smoking habits (Emery et al., 1978). 
The importance of nutritional factors, particularly vitamin A, in 
the aetiology of lung cancer is now being realised, and has been 
discussed earlier. Also, deficiency of vitamin A may predispose 
smokers to develop lung cancer. In liver and lung tissues of mice 
and hamsters, vitamin A has been shown to inhibit the activity of 
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enzymes that metabolize polynuclear aromatic hydrocarbons (Hill and 
Shih, 1974). Thus, the risk of developing lung cancer may be 
reduced in the presence of adequate vitamin A. - In fact, a recent 
study has revealed that high dietary intake of vitamin A reduces the 
relative risk of lung cancer, particularly in heavy smokers (Mettlin 
et al. ', 1979). 
Pathology 
Bronchial carcinoma is the commonest primary tumour of the lung.. 
Usually, the tumour forms a mass surrounding the main bronchus-to the - 
lung or to one lobe (hilar type). Lymphatic spread often produces 
furtheý nodules in the mucosa towards the bifurcation of the trachea. 
The caycinoma narrows the affected bronchus causing obstruction. Less 
frequently, the tumour may originate from a peripheral bronchus 
(peripheral'type). ' Early and widespread invasion of the lymphatics 
occurs and may extend to the pleura. 
Metastases are widespread and may involve virtually any organ in 
the body. There is a special tendency for the formation of 
secondary tumours in the brain, which may overshadow the primary 
bronchial tumour clinically. Metastases in bone are common, the 
thoracic vertebrae being frequently involved. Widespread metastases 
may occur from a small and clinically silent bronchial carcinoma. 
Histological types 
There are four main histological types of bronchial carcinoma, 
namely: 
(1) squamous cell carcinoma 
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(2) oat cell carcinoma, 
(3) adeno carcinoma 
(4) undifferentiated carcinoma 
The structures may be mixed in some, tumours. 
Squamous-cell-cardinomais the most commol 
cancer, -, representing approximately 45% of all 
presents-macroscopically as a denses whitish, 
flaky surface. ý It arises from the bronchial 
undergone squamous metaplasia, areas of which 
mucosa-of cigarette smokers (Auerbach. et al., 
chronic -bronchitis,.. - ý-, k 
i form of bronchial 
lung malignancies., It 
hilar mass, -often-with a 
epithelium which has 
are seen in the bronchial 
1961) and patients with 
---oat cell carcinomas account for about 35% of the total number. of 
cases, of lung cancer. They Usually arise near the hilum of the lung, - 
and are composed ofývery short, darkly staining, spindle cells that 
may appear oval or round. Some oat cell tumours secrete ACTH 
(adreno-co. -ticotrophic hormone) which causes adreno-cortical hjPerplasia 
(Odell, 1974). 
_'. 
Adenocarcinoma is the least common of the four main types and is 
composed of cuboidal or columnar cells, some of which secrete mucus. 
Sometimes these tumours may have a distinct papillary structure or they 
may. be more schirrous. Adenocarcinomas account for 5- 10% of 
primary lung cancers and more than half arise in the more peripheral 
intra-pulmonary sites. 
Clinical features 
The vast majority of patients with carcinoma of the lung present 
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with one or more symptoms associated with the le of sion. 06iy 5%- 
th6 paiients-are asymptomatid and have a tumour suspected on''routine 
physical examination or ch . est radiog I raphs. The symptoms 11 produced 
by centrally locaiýd-lesions are frequently related to bronchial 
invasion, irritation, ulceration or partial occlusion. These include 
co . ugh, haemoptysis a'nd wheezing. The cough is per'sistent, 'pro'gýessive 
and usually non-productive. A peripheral lesion may become quite 
large with invasion of the pleura and chest wall before it is diagnosed, 
and'associated pain may be'the symptom in the'se patients. 
The prognosis of lung cancer patients is very poor and about 80% 
of patients die within 
_a 
year of diagnosis. About 30% of patients 
with small peripheral lesions in the lung survive more than five years, 
after the operation, whereas the comparable figure for'all lung cancer 
patients is 5- 1OZ. Survival is longer in patients wi. th squamous cell 
carcinoma and much shorter in those with undifferentiated and 
adenocarcinoma (Clinical Oncology, 1978). 
1.5.2. Testicular teratoma: Metastatic lung cancer 
Lung is a, great filter of the blood stream and it is not, 
surprising that a. wide variety of tumours may give rise to. pulmonary 
metastases. jesticular teratoma is a highly malignant, tumour which, 
often, metastasises to the lung in the early stages. Recently it has 
been pointed out that about 20% of patients with clinical. Stage I, 
disease. harbour occult pulmonary metastases. (Editorial, Cancerltopics, 
1979)., tumours have now been recognised. as, 'one of 
the 
commoner malignant diseases in males up to the age of 35 years. ýTabl, e 1.1) 
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In this age group, more-than 95% of the tumours are germinal cell"' 
tumours, 'namely seminomas and teratomas. Although seminomas are 
more common, teratomas are also of great importance as they are much 
more-malignant-than seminomas. 
Table 1.1 Mortality from selected malignancies for males by, ages 
England and Wales,, 1970. 
Site. , Death rate/Incidence per million population 
Age 
15-24, 
Testis, 
Hodgkin's disease 
Myeloid leukaemia 
Trachea; bronchus,, lung, 
11/28 
16/38 
12/14 
3/3 
25-34. ý, 
22/71 
19/47 
15/17 
14/19 
Statistics from Registýar General's Statistical Review of England 
and Wales, 1970 and supplement on Cancer 1969-70 (from Oliver 1979). 
A teratomatous tumour consists of a chaotic array of ectodermal, 
endodermal and mesodermal derivatives of varying degrees of 
differentiation and Malignancy, along with areas of typical embryonic 
carcinoma. Teratoid elements frequently include smooth muscles 
connective tissue, cartilage, bone, gastro-intestinal. and respiratory 
epithelium, nervous and cutaneous structures. In a majority of 
patients, the secondaries that arise from the 'primary tumour are also 
teratomatous,, -with-varying degrees of differentiation. Metastases 
usually occur in the following sites in the order of frequency: lung, 
abdominal lymph, nodes, nodes above the diaphragm, liver, brain, kidney, 
bone and other sites (Pugh and Cameron, 1976). 
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Pathological staging of teratomas suggested by Pugh and Cýmeron 
t, 1 
(1976) is shown in table 1.2. 
'Table I. L Pathological staging of non-seminomatous germinal 
cell tumours of the testes. 
teratoma malignant malignant malignant 
differentiated teratoma teratoma teratoma 
intermediate undifferentiated trophoblastic 
Recently, it has been discovered that the tumour cells from a 
. substant6l number of patients synthesize marker proteins such. as 
a-fet6protein (aFP) and $-human chorionic gonadotrophin (aHCG) and a 
spe6ific testicular iso. -renzyme of lactic dehydrogenase (LDH). 
ýAlphafetoprotein and ý-HCG have been demonstrated within the tumour 
cell cytoplasm using the immuno-peroxidase technique (Heydermann'et al., 
1976). However, this technique has still not improved. the pathological 
staging of tumours. After the hittological type, the clinical stage 
(Table 1.3) and bulk of the tumour are the most important predictors 
of 'long term outcome (Tyrrell and Peckham, 1976). 
Table. 1.3. Staging of testicular tumours. (after Peckham and 
McElwain., 1976). 
Stage 
I Tumour confined to the testis. 
Metastases to para-aortic region but no metastases 
above diaphragm. 
III Metastases above diaphragm but only detectable in 
lymph nodes. 
IV Metastases in non-lymphoid organs, lung, liver, 
bone, skin and central nervous system. 
30. 
However, earlyýdetection does not necessarily mean better, prognosis. 
Injact, Miller and Selieli. d (1971) have pointed out. that some cases 
with a longer-history may have a better prognosis. Nevertheless, . 
early diagnosis may make the tumour more amenable to treatment. 
1.6 
_NUTRITIONAL 
PROBLEMS OF-THE CANCER PATIENT 
The uncontrolled growth of the tumour occurring in active neoplastic . 
disease may have unfavourable metabolic consequences. The growing 
tumour'may derange the metabolism of the host because of its own 
requirement for nutrients (Basu et al , 1973)., In fact, many.. 
patients with cancer are often malnourished, either as a result of the 
disease or as a'consequence of increasingly aggressive forms of 
treatment often of'a multiple nature (Dickerson and'Tredger, 1977; 
Dickerson and Basu, 1978; Leading article, Brit. Med. J., 1979). 
SoMetimes. the tumour may cause physical interference with strategic 
organs. '- Thus, patients with cancer of the upper alimentary tract are 
6ften malnourished as u result uf dezreased food intake due to partial 
or complete obstruction. The involvement of the pancreas, pancreatic 
duct-or common bile duct may lead to impaired digestion or absorption 
of fats or fat-soluble vitamins. 
In contrast, certain metabolic abnormalities occur which are not 
the immediate result of mechanical interference with recognisable 
structures (Costa, 1963). This poorly understood state of ill-health 
observed'in-some patients with advanced cancer is termed cachexia. 
It is characterised by loss of body weight, associated with anorexia, 
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increased basal metabolic rate and energy expenditure, marked 
weakness, loss of body fat and protein, anaemia, water and 
electrolyte abnormalities (Theologides, 1977). This condition 
is more common in patients with tumours of the alimentary tract 
than in patients with breast and lung cancer (Dickerson and 
Basu, 1978). Cachexia is a genuine clinical syndrome and may 
be reversed by surgical removal of the total malignant growth 
or when complete remission of the tumour is achieved by radio or 
chemo-therapy (Theologides, 1977). 
The cause of cachexia is at present unknown. It has been 
suggested that, cancers frequently produce peptides or other small 
molecules, which have beenýcalled, toxohormones and that these act 
upon the tissues, of the host to release amino acids into the 
metabolic pool, which are used for continued tumour growth'(Hall, 1974). 
Theologides (1974) has suggested that these substances enter host* 
cells, and, through successive transitions, activations and 
inactivations of normal enzyme - systems throw the metabolism of th., -,, 
host into a chaotic state. ' This metabolic chaos results in increased 
release of amino acids into the metabolic pool. Studies on 
experimental animals have shown that the tumour serves as a 'nitrogen- 
trap'Ancorporating amino acids into the tumour in an essentially 
one-way passage from the metabolic pool to the tumour (Mider, 1953). 
Hypoalbuminaemia has been observed in many cancer patients (Mider 
et al., 1950; Calmon, 1978) and this is considered to be due mainly 
to decreased albumin synthesis (Steinfeld, 1960; Mariani et al., 1976) 
and partly to protein losing gastroenteropathies (Waldmann et al, 
1974). 
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Watkin (1959) showed extensive losses in body fat in the cancer 
patient. The mechanism by which the tumour induces lipid 
mobilisation is not clear. -ICancer patients also show altered 
carbohydrate metabolism, connected to the derangement of protein and 
lipid metabolism. The pathway of gluconeogenesis is greatly 
augmented (Gold, 1974). Also, some patients with neoplastic disease 
have a decreased sensitivity to insulin (Marks and Bishop, 1957). 
, Deficiencies of vitamins other than vitamin A have also been 
observed in patients with cancer at different sites in the body. 
(Dickerson and Basu, 1977). A significant proportion of patients 
with advanced malignant disease have been found to be at risk of 
thiamine deficiency, as judged by the stimulating effect of 
transketolaseenzyme activity. by thiamine pyrophosphate (Basu et al., 
1974a). The requirement of folic acid is increased in patients with 
cancer'(Einhorn and Reizenstein, 1966). This observation is supported 
by the'demonstratio'n of'increased folic acid reductase activity, 
following lnfect-iun of mouse kidney cell cultui-es with polyo-. -. Ia virus 
(Frearson et al., 1966). Also, Rao et al. (1965) have reported lower 
serum'folic acid in patients bearing malignant tumours as compared to 
the*control-group. Abnormalities in vitamin B6 and tryptophan 
metabolism have been observed in a significant number of patients with 
Hodgkin's disease and in some patients with carcinoma of the breast 
(Chabner et'al., 1970). 
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Ascorbic acid plays a number of important roles in the body. 
Kramsner and Dymock (1974) have shown that tissue stores of ascorbic 
acid are depleted in patients with advanced malignant disease. Low 
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leucocyte ascorbic acid levels have been found in patients with breast 
cancer and lowest values were found in patients with skeletal 
metastases (Basu et'al., 1974b). The ascorbic acid concentration in 
the plasma and leucocYtes of children with acute lymphoblastic leukaemia 
were significantly lower compared to normal age matched children, (Kakar 
et al. 
-, 
1975). 
These nutritional deficiencies may be aggravated by the specific'' 
treatment'usedto control. the disease, namely surgery, radiotherapy or 
chemotherapy. 
TREATMENT OF CANCER AND ITS 
EFFECT ON NUTRITION 
Surgery , can cure the disease only when it is localised'to the'-', 
tis'sue, of'origin''and its regional draining lymph nodes'. ý Radiation 
iheApy. -is often'employed in the treatment of localised, but inoperable 
tumours. Systemic treatment with drugs or hormones may be used'when 
the I disease is I in the disseminated, inoperable stages. - More recently, 
immunotherapy has been employed either by itself, or in combination 
with other'm6de-s of therapy in the treatment of certain types of cancer. 
Multimodal'therapy is currently favoured, as it yields better survival 
rates and more effective tumour remission. 
1.7.1. Treatment of lung cancer. 
Surgical extirpation of bronchogenic'carcinoma remains the only 
consist6n't meihod of achieving a cure (Ashor et al., 1975). - Lobectomy, 
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when technically feasible, is to be preferred, since it gives 'survival 
rates as good as pneumonectomy (Higgins and Beefe, 1967). Moreover, 
it is specially advi. sable when pulmonary function is borderline. The 
hilar lymph nodes should be removed with lobectomy or pneumonectomy; 
however, if they are involved the chances of cure are remote. 
Oat cell carcinoma cannot be cured surgically (Medical Research 
Council, 1966). The disease invariably extends outside the chest and 
there is bone marrow invasion in 50% of the cases. Treatment consists 
of radiation to the lung and intensive chemotherapy for-metastatic 
di sease. 
ýI 
Of all patients with pulmonary malignancy, 50% or more of the 
tumours are found to be unresectable at the time of the patient's 
initial hospital evaluation. (Thompson, 1967). Radiation therapy may 
be useful for palliation in inoperable patients with symptoms-(Roswit 
et al., 1968), but is seldom indicated in the symptom-free patient with 
disseminated disease. (Durrant et al., 1971). In rare cases it may be 
curative in patients with localised disease who cannot tolerate surgery 
for medical reasons. 
Radiation therapy often induces significant anorexia and loss, or 
alteration, of sensation of taste which may considerably decrease the 
food. intake. Many patients suffer considerable weight loss between 
initiation 'and completion of therapy. 
-Chemotherapy 
is used primarily as an adjuVant, following surgical 
resection or as a palliative tool in patients with unresectable or 
metastatic carcinoma. - The results of single alkylating agents such 
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as cýclophosphamide'and the nitrosoureas have . been disappointing 
(Shields et al., 1974). Considerable enthusiasm has been generated 
for intermittent long-term adjuvant chemotherapy, particularly when. 
given in combination with immuno- or radiotherapy. (Israel and 
Depierre, 1976; Donovan et al., 1976). Encouraging results have 
recently been reported using a regimen of combination chemotherapy 
with radiotherapy to the chest lesion and prophylactic brain 
irradiation in oaý cell carcinoma (Greco et al., 1978). ý 
Long term survival of occasional patients in whom tumour h4s 
been left behind after operation and the well-known fact that patients 
with tumoOrs of similar extent, situation and histological type maY 
progress at widely different rates suggests that the immune 
responsiveness of the individual plays an important part in determining 
the progress of the cancer; Furthermore, some indices of. immune 
competence are depressed in lung cancer patients and the severity of 
this depression correlates inversely with survival rate (Liebler et al., 
19771. There 43, therefore, considerable Intcrest at present on*the 
role of immuno-stimulants in the treatment of lung cancer. Promising 
results have been claimed for both BCG and levamisole as adjuvants to 
surgery, but it is too early to assess whether these agents have a 
significant role. 
1.7.2. 'Treatme'nt'of testicular teratoma. 
Until the introduction of effective chemotherapy, radiotherapy 
or surgery provided the only hope of cure for the patient with malignant 
teratoma of the testis. Thus, more than 50% of the patients died of 
uncontrolled malignancy and cures, with rare exceptions, were confined 
36 
to patients with relatively early stage of the disease. The' 
demonstration that a small proportion of patients with advanced 
disease could. be cured with single agent chemotherapy, particularly 
with actinomycin D (MacKenzie, 1966),. provided the first hint thaf 
teratomas, recognised as chemosensitive tumours for a long time might 
eventually prove to. be curable by chemotherapy. 
The primary testicular tumour is treated by orchidectomys, with 
high ligation, of the spermatic cord. Prophylactic radiotherapy is 
often given to the normal para-aortic lymph nodes in stage I disease 
and to the mediastinal lymph nodes in stage II disease (Peckham and 
McElwain, -1976). Even With the best results from surgery or 
radiotherapy, 25% of stage I and II tumours will recur at some stage 
and-Will also need chemotherapy. Li and co-workers (1960) first 
reported some-success against disseminated testicular cancer with a 
combination of actinomycin D, chlorambucil and methotrexate. Howevers 
there was no major change in survival rates until the introduction of 
a combination of vinblastine and bleomycin (Samuels et al., 1976). 
They reported a greatly improved overall response rate of 75% and a 
complete response of 32% in 50 patients with stage III testicular 
cancer. ' Spiegel et al. (1978) als-o showed that the combination of 
vinblastine and bleomycin gave a higher response rate than vincristine 
(a. non-myelosuppressive drug), actinomycin D and bleomYcin. Very 
recently, Peckham et al. (1979) have reported disease free survival 
rates in 81% of patients with bulky abdominal nodes and those with 
limited lung disease. 
Higby and co-workers (1974) first showed that cis-diamine dichloro 
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platinum II (gis DDP), would produce tumour regression in patients 
with, metastatic testicular tumours. Nine of the 11 patients they 
treated responded, 3 of whom had complete disappearance of the 
tumour. Subsequent work by Einhorn and co-workers (1977) 
incorp orating cis;. DDP has shown that the combination, of vinblastine,. 
bleomycin and, cis-DDP, is-an effective regimen and that-complete 
remission confers a high probability of long-term disease-free 
survival and, probably, cure. These recent developments have greatly 
transformed the prospect for the-patient with metastatic testicular 
teratoma-, t I 
, -,,, -. Howeyer, the response to chemo- or radio therapy is largely 
influenced by. tumour volume and the prognosis is decreased in bulky 
metastatic, disease. Also, these drug combinations cause toxic side 
effects, -which may., adversely affect the health and nutritional status 
of the patient. 
Drugs used in chemqthenýpy. 
(a) Bleomycin 
Bleomycin is an antitumour antibiotic first isolated by Umezawa 
and co-workers (1966) from cultures of Streptomyces verticillus. 
More than 200 different bleomycins have been isolated and characterized 
as complex, basic glycopeptides (Umezawa,, 1971). The various 
bleomycins differ from each other only in the terminal cation moiety, 
which consists of an amine or polyamine moiety (Fig 1.5). Bleomycin A2 
is used clinically in the treatment of oesophageal carcinoma, ýodgkinls 
disease, non-Hodgkin'sLymphomas*, squamous cell carcinoma of head'and 
neck, uterine cervix and testicular carcinoma (Carter et al., 1977). 
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Bleomycin first removes the thymine from native DNA in vitro,, by 
hydrolysis of the N-glycosidic bond, without modifying the'deoxyribose 
moiety (Fig 1.6). in a second step, single strand scissions occur. 
at the sites of non-glycosidic deoxyribose moieties, resulting in the 
formation of 3'-hydroxy and 51-phosphate termini (Muller and Zahn, 1977). 
It is suggested that-bleomycin is bound to DNA by interaction of the 
positively charged amine moiety with a negatively charged phosphate 
group in DNA; intercalation seems to be involved in the binding. 
In intact cell systems, bleomycin reduces DNA synthesis selectively 
by the induction of Single strand breakages; RNA synthesis as well as 
protein synthesis is unaffected. Cell progression is inhibited by 
bleomycin at the end of the S-phase and early half of the G2 phase, 
thus. showing the drug to be a possible synchronizing agent (Muller and 
Zahn, 1977). -Bleomycin is detoxified by a bleomycin-inactivating 
enzyme which is present in all tissues other than the lungs and skin 
(Umezawa, 1970). The concentration of inactivating enzyme was found 
to be significantly lower in sýuemous cell carcinoma than in sarc6ma 
of mice (Umezawa, 1973). Thus, it may be effective against squamous 
cell carcinoma. The activity of bleomycin is dependent upon uptake, 
inactivation and activation leading to tissue and organ specific 
actions. 
(b) Vinblastine 
Vinblastine, sulphate (Velban), used in combination with bleomycin, 
is an alkaloid (Fig 1.7) originallY isolated from the periwinkle, 
Vinca rosea (Johnson et al., 1960). The mechanism of action of. 
vinblastine is not very clear. In low concentration, vinblastine 
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Figure 1.6 Schematic representation of bleom. ycin caused 
degradation of DNA (from Muller and Zahn, 1977). 
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arrests cell division in the metaphase (Palmer et al., 1960). It 
causes reversible disruption of the mitotic spindle (Lettre, 1966). 
The spindle fibres are long strands of microtubules connectiýg, 
the two centrioles in the dividing cell to the kinetochromes of the 
chromosomes. The spindle fibres direct the segregatibn of the 
sister chromatids to the opposite poles during anaphase. -The spindle 
fibres contain microtubular proteins such ast tubulin. Vinblastine 
and other Vinca alkaloids have been shown to interact with tubulin 
(Creasy, 1975). These binding interactions may cause dissolution of 
the spindle, thus preventing migration of the sister chromatids 
(Fig 1.8). However, there-is no conclusive evidence to puggest that 
cytotoxicity is due entirely to the ability of Vinca alkaloids to 
cause metaphase arrest. Inhibition of nucleic acid synthesis by 
Vinca alkaloids has also been reported. (Jones et al., 1966). Creasy 
(1978) suggests that inhibition of biosynthetic processes and damage 
to macromolecules on exposure to Vinca alkaloids may bring about cell 
death 
.I 
(c) Cis-diamine dichloro platinum (II) 
The recent discovery of anti-tumour activity in square planar 
co-ordination complexes of platinum has revolutionized cancer chemotherapy 
(Rosenberg et al., 1969). Cis-diamine dichloro platinum PQ -. 
Cis DDP (Fig. 1.9) is now in clinical use against a wide variety of 
cancers in man, including testicular malignancies (Rosenberg, 1971; 
Higby et al., 1974). 
41 
R= CH 3- vinblastine 
R= CHO - vincristine 
Figure 1.7 Structure of. vinbl6sti. ne 
metaphase 
possible site of action 
vinbl'astine 
(and vincristine) 
anaphase 2ýq 
telophase 
X. 
lit Z- 
j 
Fig 1.8 Diagrammatic representation of the mitotic 
spindle and the site of action of vinblastine 
(from, Pratt, 1973). 
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Fig. 1.9. Structure of cis-diamine d'ichloro 
platinum (II) - cis-DDP. 
Its mode of action is still not clear. The sites of the 
primary lesions on the cells, leading to tumour destruction are 
believed to be on the nuclear DNA (Rosenberg, 1977). Howeverý* 
testsconducted in vitro indicate a large number of possible modes 
of'reaction of the nucleic acid and its constituents. Events 
subsequent to the primary attack that lead to anti-tumour activity. 
are largely unknown. There is some evidence suggesting the 
involvement, of the host's immune response in the anti-tumour 
activity (Rosenberg, 1977). 
Cis-DDP has several advantages as an anti-tumour agent: 
(1) it exhibits marked anti-tumour activity 
(2) it is a broad spectrum drug that is active 
against drug-resistant as well as drug- 
sensitive tumours 
(3) it is active against both slow-growing 
and fast-growing tumours 
(4) it has some activity against tumours 
insensitive to S-phase inhibitors 
(5) it is useful against disseminated as 
well as solid tumours 
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1*. 7.4. Cell cycle. and combination chemotherapy. ' 
The cOAination of several anti-tumour agents in enhancing the 
efficacy of treatment of cancer is based mainly on their inhibition 
'of different phases of the cell cycle. 
The proces ,s of'cell division involves several stages. Firstly. 
the daughter'cells produced by a previous division undergo a period 
of cyto-plasmic g'rowth in which they increase in size and synthesize 
products needed for specialized cell function. This initial period 
of growth is called_IG I and involves a rapid turnover of RNA which 
in turn directs the synthesis of proteins. Most tissue cells spend' 
theiý lives in G, and cannot subsequently de-differentiate and 
divide. 
A few cells, called stem cells or immature G, cells, retain the 
capacity to respond to a'replicative stimulus. After appropriate 
initiating stimuli, such stem cells begin to synthesize products 
necessary for DNA synthesis (late G, phase). G, is therefore, a 
period of extremely variable length, ranging from a few hours to many 
years. 
Thereafter, the cells enter the 'S' phase, a rather restricted 
period of intense DNA replication. During this period, the purine and 
pyrimidine bases are synthesized, converted to nucleotides and 
combined into new strands of DNA that are complimentary to the single 
components of the double helix. During the S phase many targets for 
chemotherapy are provided by the need of the cells to synthesize 
purine'and pyrimidine bases, the appearance of enzymes concerned with 
biosynthesis, phosphorylation and polymerisation of. bases and the 
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opening up of the double helix with uncovering of multiple reactive 
sites along the DNA chain (Brule et al., 1973). A cell that enters 
the S phase is committed to proceed through all the subsequent. steps 
of the mitotic cycle. 
Following the S phase, there is a-rather brief period of 
metabolic consolidation of the cell; this phase is-called 'G2'. It, 
is a period during which general cytoplasmic proteins and possibly 
histones and other DNA associated proteins are synthesized. 
The cell then enters the mitosis, or W phase. In most cells, 
regardless of the tissue or even the species of origin, M phase lasts 
for about an hour. 
Tumour cells also foll'ow the same cycle of events. Three known 
factors that affect the rate of tumour growth are: (1) the rate of 
replication of proliferating cells (cell cycle time) (2) the proportion 
of total cell population that is proliferating (g., owth fracti, on) and 
(3) the rate of cell loss from the tumour (Steel et al., 1966). The 
rate of cell proliferation depends on cell type and is influenced. by 
the availability of nutrients including oxygen. 
Several authors have reviewed the mode of action of antineoplastic 
agents (Stock, 1975; Krakoff, 1977). Some antineoplastic agents are 
cell cycle dependent, while others are not. The site of action of 
some antineoplastic drugs in the cell cycle is shown in Fig. 1.10. 
The anti-tumour agent bleomycin, reacts with DNA either in the late 
S phase or G2 phase. Vinblastine, however, inhibits cell division 
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possibly in the late G2 and the M phase. The combination of ' 
vinblastine with bleomycin would greatly enhance the anti-tumour 
effect of each drug. Moreover, the different biochemical 
properties of these drugs would enable the toxic side effects to 
be spreadý The toxic side effects of bleomycin are seep in the 
lungs and skin (Umezawa, 1970). . In fact, impairment 6f pulmonary 
kfunction is the dose-limiting factor (Luna et al., 1972), but, it is 
exceptional,, in that it does not depress the bone marrow. Vinblastine, 
however, is-notably toxic to the bone marrow (Creasy, 1975). Thus a 
combination of, these drugs would, enable the use of the two drug? in 
sufficiently high concentration to produce a marked anti-tumour effect 
with, minimal. side effects. . 
In contrast, cis-DDP is not cycle specific 
and-its dose-limiting factor is toxicity to the kidney (Gottlieb and, 
Drewinko,,, 1974). - The use of cis-DDP in combination with vinblastine 
and bleomycin would be expected to achieve a greater degree of 
specificity, and enhance the efficacy of treatment. -Also,, the emergence- 
of resistance is-likely to be delayed when a combination of drugs is 
tv, od. 
1.7.5. Adverse effects of chemotherapy. 
An ideal chemotherapeutic agent should have the capacity. to 
Interfere with a metabolic pathway that is unique-to the neoplastic 
cells and necessary for their survival, without affecting normal cells. 
In addition, the drug should have characteristics that enable it to 
reach all the neoplastic cells at a sufficiently high concentration.. However, 
a consistent, exploitable biochemical difference between normal and 
malignant cells has not been found so far. 
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The use of cytotoxic drugs is based on the principle that 
neoplastic cells have a faster rate of multiplication when compared 
to normal cells. The cells of many kinds of cancer divide more 
slowly than their normal counterparts. In many instances, however, 
they-spend a longer time in the actual process of cell division, so 
that, neoplastic tissue-often contains a greater percentage of cells 
undergoing division at any one time. This may confer a certain 
degree of selectivity in the mode of therapeutic action. However, 
the action of most cytotoxic drugs is not selective with respect to 
normal, and neoplastic cells. When these drugs are employed in. doses 
sufficient to inhibit the growth of tumour cells, they will also have 
an, effect on normal. cells possessing a high turnover rate, such as 
cells of the bone marrow, gastro-intestinal tract, hair follicles and 
germinal epithelium. 
The magnitude of these effects will depend on the nature of the 
drug, 
-dosage, duration of 
treatment, changes in rates of excretion or 
m: tabolism and also upon individ.! al susceptibility. Geneially 
speaking, better nourished patients are able to withstand higher doses 
of. drugs (Shils, 1975). Nutrition also affects the rates at which 
drugs are metabolized (Basu and Dickerson, 1974) and hence their 
toxicity. 
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1.8 NUTRITIONAL PROBLEMS ASSOCIATED 
WITH CHEMOTHERAPY OF CANCER 
Nearly all chemotherapeutic agents against cancer adversely 
affect dietary intake and weight loss is often observed during 
aggressive chemotherapy for cancer (Donaldson, 1977). A 
summary of the effects of different drugs used in chemotherapy 
is given in table 1.4. Bleomycin, vinblastine and many oth er 
drugs cause anorexia, nausea, vomiting and diarrhoea 
, 
(Donaldson, 1977). The changes in the intestinal mucosa caused 
by antineoplastic agents are of great importance, as they may well 
-result in malabsorption of nutrient S. Intestinal mucosal changes 
associated with altered intestinal function have been observed 
with Vinca alkaloids (Dowling et al., 1970). 
The treatment, with cytotoxic drugs may induce or aggravate 
deficiencies of certain micronutrients such as vitamins. For 
example, thiamine deficiency observed in some patients with advanced 
cancer was exacerbated by treatment with 5-fluorouracil. Studies 
conducted in vivo and in vitro suggest that 5-fluorouracil causes 
a marked decrease in hepatic concentration of thiamine, with a 
concomitant decrease of coenzyme activity (Basu et al., 1979). 
Furthermore, the antitumour effect of tKýosem:,, rav6zbýe is enhanced 
by the administration of thiamine (Crim et al., 1967). Treatment 
with thiosemicarbazone (3-ethoxy 2-oxo butyraldehyde) an active 
antitumour agent against transplanted tumours led to a fall in the 
levels of thiamine 'and pantothenic acid in the livers of experimental 
animals. Supplementing tumour bearing rats with thiamine and 
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pantothenic acid increased the activity of the antitumour agent 
(Petering et al., 1964). 
The effect of antitumour agents on plasma vitamin A in cancer 
patients has not been investigated. However, there is. some 
evidence to suggest that vitamin A enhances the action of some 
antitumour agents in animal models. For example, vitamin A 
potentiates the antitumour effect of cyclophosphamide on mammary 
adenocarcinoma, of mice (Anton and Brandes, 1968). Also, vitamin A 
enhances the antitumour effects of BCNU (1.3 bis (2-chloroethy)) 
1-nitroso urea) and to a lesser degree cyclphosphamide in murine 
L 1210-leukaemia (Cohen, 1972; Cohen and Carbone, 1972). 
Furthermore, Basu et'al., (1974c) have demonstrated an accentuation 
of-, the cell killing effects of chlorambucil by phenobarbital, 
caffeine and vitamin A. 'Moreover, a combination of vitamin A and 
5-fluorouracil has been shown to cause marked regression of a skin 
tumour, ýkeratoacanthoma, in rabbits. (Prutkin, 1973). 
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1.9 CONCLUSION AND PLAN OF PRESENT STUDIES 
Considerable importance is now attached to the role of .. - 
nutrition in the pýthogenesis and prevention of cancer as 
evidenced by a number of symposia. and reviews on the subject. 
(Nutrition and Cancer, 1976; Nutrition and Cancer, 1977; 
Nutrition and Cancer Therapy, 1977). In this connection 
vitamin A is of particular interest. Deficiency of vitamin A 
has been shown to give rise to metaplastic changes in epithelial- 
tissues, specially in'the respiratory, gastro-intestinal and.. 
urogenital tracts. These changes may later progress to neoplasia. 
Studies on experimental animals revealed that natural or synthetic 
retinoids have the ability to reverse such changes. Furthermore, 
retinoids in high doses prevent chemical carcinogenesis'in 
epithelia such as that of the respiratory tract. 
Epidemiological evidence also points to an association between 
Atamin'A and-epithelial cancar -in man, particularly in ihe lung. 
Dietary intake of vitamin A has been shown to be negatively associated 
with-lung cancer at all levels of cigarette smoking. -A recent study 
has also, revealed that high vitamin-A intake reduces the relative 
risk, of, development of Tung cancer in heavy smokers. In view of 
the fact that lung cancer is a disease which has a high incidence 
and a poor prognosis, it is of paramount importance to study the 
relationship between vitamin A and lung cancer. 
-The reports on the subject however, are conflicting and scanty. 
Therefore, it was considered necessary to study the serum vitamin A 
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status oflung cancer patients in a systematic manner in order to 
clarify the earlier findings. 
The' demonstration of an association between lung cancer and 
vitamin A'deficiency does not necessarily reveal a role for the 
vitamin in the causation of the disease. Furthermore, other 
factors may contribute to the low levels of vitamin A. A study 
of some'of'the factors which may affect plasma vitamin A was 
undertaken in the hope that it would provide an insight into the 
mechanism by which the low circulating levels were produced. 
It seemed to be of interest to study another type of cancer 
where the malignant disease arises secondary to a primary tumour 
elsewhere. Testicular teratoma is a highly malignant tumour which 
often metastasizes to the lung in the early stages., The vitamin A 
transport system was also studied in such patients. 
Unlike primary lung cancý,. -, disseminated testicular terato. ýa 
is very sensitive to chemotherapy. However, the aggressive 
chemotherapeutic treatment given to such patients often causes toxic' 
side effects. Therefore, it was considered necessary to 
investigate the effects of these cytotoxic drugs on vitamin A. 
Moreoverý no studies have sb far been conducted on the effect of' 
these drug regimens on vitamin A. The effect of combination 
chemotherapy on the plasma vitamin A transport system was followed in 
patients having metastatic testicular. teratoma treated with the 
following drug regimens: 
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(1) vinblastine and bleomycin - Samuels regimen 
(2) vinblastine, bleomycin and cis-diamine dichloro 
platinum (II) - Einhorn regimen.. 
The variation of vitamin A status was compared with that of other 
vitamins such as vitamin E, ascorbic acid, thiamine and pyridoxine. 
A parallel investigation of the effects of these antitumour 
agents on the vitamin A status of normal healthyrats was also 
carried out. 
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CHAPTER TWO 
VITAMIN A AND LUNG CANCER IN MAN 
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2.1 INTRODUCTION 
-A preliminary'study of vitamin A in lung cancer patients 
revealed significantly lower concentrations of plasma vitamin A 
as'compared to normal healthy subjects, or to patients having 
non-malignant. lung-diseases (Basu et al.,, 1976). However, 
Cohen et 61. (1977) did not observe a significant difference 
between plasma concentrations of lung cancer patients and normal 
healthy subjects. These observations seemed to require 
clarification. ' Moreover, it seemed necessary-to study possiýle 
factors which could account for the low circulating concentrations 
of vitamin A. since this might provide insight about its causation. 
The, concentration of vitamin A may be altered by several 
factors. Thus, it is reduced by a low dietary intake of vitamin A- 
or its precursors. Blood levels are also reduced by malabsorption' 
from the gut. Vitamin A*is transported in the blood in association 
with a'specifi--. -rotein - retinol-binding prctein, which in turn . 1-' 
circulates as a biprotein complex with prealbumin (Kanai et al., 1968). 
It is possible, therefore, that low circulating levels of the vitamin 
could be due to a decreased availability of the carrier protein(s). 
Additionally, low blood levels might result from an increased need 
for vitamin A, due to the presence of the tumour. 
Vitamin A deficiency as a result of decreased dietary intake is 
relatively rare in developed countries. However, in some conditions 
malabsorption of vitamin ý occurs, 'but, i. n such conditions it seems' 
likely that other fat-soluble vitamins would also be poorly absorbed. 
,. -1 1 
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Vitamin E, another fat-soluble vitamin is an important factor in 
the biological utilisation of vitamin A. The absorption of 
vitamin Vis impaired in vitamin E-deficient rats and oral 
supplementation with vitamin E markedly increased the utilisatio; 
of vitamin A (Ames, 1969). In a recent study, oral administration 
of. vitamin E to normal and vitamin A-deficient children resulted 
in a significant increase in plasma vitamin A concentration in both 
groups (Jagadeesan and Reddy, 1978). 
,. Smith and co-workers (1973c) pointed out that zinc may be. 
essential in the mobilisation of vitamin A from tissue stores. 
These, workers found that zinc-deficient rats had low plasma ý 
: concentrations of -vitamin A, inspite of adequate liver stores of 
the vitamin and-zinc-therapy resulted in mobilisation of vitamin A 
, from, the, liver, It is possible, therefore, that low plasma vitamin A 
. 
levelsAn lung. cancer patients might result from,. a deficiency of zinc. 
Cristaelis, et al.. (1976) sujgested that rcreased ACTH. (adreno- 
corticotrophicUmone) -secretion, followed by increased production. 
of glucocorticoids in the adrenals, may occur in lung cancer patients, 
either due to the presence of tumour cells creating astate of stress, 
or--to ectopic. production by the lung tumour. These glucocorticoids 
may antagonise tissue vitamin A and in turn lead to low plasma levels 
of the vitamin. 
Some of these-factors were studied in a series of patients with 
newly'diagnosed bronchial-carcinoma. Age matched patients with non- 
malignant lung diseases and other non-malignant diseases served, as 
controls.. 
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2.2 PATIENTS 
Twenty six newly diagnosed, histologically proven lung 
cancer patients (22_males, 4 females) admitted for treatment 
to Redhill General Hospital, East Surrey were studied. Their 
ages ranged from46-82 years with a mean value of 64.7 years 
(Table 2.1). Ten patients had squamous cell carcinoma, five, 
oat cell carcinoma, three adenocarcinoma and eight had 
undifferentiated carcinoma. These patients had not previously 
received surgery,, radiotherapy or chemotherapy., 
The results of these patients were compared with those of 
ten patients (7 males, 3 females) having non-malignant lung 
diseases, such as acute or chronic bronchitis, bronchiectasis, 
(control group I). Their ages ranged from 47-74 years., with a 
mean value of 60.3 years (Table 2.2). - The second control group 
(II) consisted of eleven patients (8 males, 3 females) having other 
non-malignant diseases such' as ischaemic heart disease. ' hiatus 
hernia, myocardial infarction and cerebro-vascular incident. Their. 
ages . ranged from 
_48-75 
years, with a mean value of 63.4 years 
(Table 2.2). The smoking habits of both lung ca. ncer patients and 
controls were noted. 
Overnight fasting blood samples were collected by venepuncture.. 
Serum was separated within two hours of withdrawal of blood, and 
divided into aliquots and stored in sample tubes covered with foil 
at -400C until analysed. The analyses 
. for vitamins A and E and 
O-carotene were carried out within two weeks of collection of the 
samples. . 
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Table 2.1. Clinical details of lung cancer patients. 
LUNG CANCER PATIENTS 
Name Sex Age 
years 
Diagnosis Smoking habits 
ci46rettes(no-) 
tobacco(oz. ). 
P. D. M 60 Squamous carcinoma 10/day - 
G. R. M 81 Advanced undifferentiated 12/day 
carcinoma stopped at 60yrs 
B. P. F 71 Undifferentiated carcinoma 20/day 
E. B. F 78 Squamous carcinoma 
F. C. M 82 oat cell carcinoma pipe, till-196 0 
F. L. M 71 Squamous cell carcinoma 20-30/day 
family history of lung 
cancer 
E. C M 54 Undifferentiated carcinoma, 5/day 
inoperable 
D. I. M 63 Broncheoalveloar adeno 20/day 
carcinoma, operable 
C. G. M 62 Oat cell carcinoma, operable . 20/day 
F-V- M 66 Squamous carcinoma 40/day 
F. B. M 78 Inoperable, undifferentiated 
carcinoma 
S. G. F 46 Undifferentiated carcinoma 7/day 
of bronchus 
R. N. M 46 Large cell, oat cell and 
undifferentiated carcinoma 
W. R. S. M 62 Poorly differentiated squamous 1 oz/day 
carcinoma 
E. T. F 66 Adenocarcinoma 10/day 
stopped 6 yrs 
ago 
J. E. M. M 60 Undifferentiated carcinoma 10/day 
J. S.. M 77 Poorly differentiated squamous Smoker 
carcinoma 
D. B. M 64 Oat cell carcinoma 80/day 
stopped in 1967 
C. M. M 64 oat cell carcinoma 60-80/day 
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Table 2.1. cont'd 
Name Sex- Age 
years. 
Diagnosis 
Smoking habits 
cigarettes (no. 
-tobacco (o 
D. W. M 49 Squamous carcinoma 2 oz/week 
W. P. M 63 Undifferentiated carcinoma 50/day 
R. P. N 57 Squamous carcinoma 30/day 
T. H. M 68 Adenocarcinoma. 10/day till 
1974 
J. R. M_ 60 Squamou s carcinoma 20/day 
C. G. M 65 Squamous carcinoma 10/day 
A. H. M '70 UncNfftvtntýQýed CavCZnor, &ct 
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Table 2.2 Clinical details of controls. 
Control group I- non-malignant lung diseases. 
Name Sex Age Diagnosis Smoking habits 
years cigarettes 
(no. ) 
tobacco (oz. ) 
M. C. m 54 Bronchitis 
G. F. m 72 Bronchitis 
V. F. O. m 74 Bronchitis 
L. H. F 68 Bronchitis 
L. D. m 65 Chronic bronchitis 
H. S. F 63 Bronchiectasis 
E. E. F 60 Cor pulmonale 
P. L. m 51 Chronic bronchitis 
J. S. m 47 Acute chest infection 
R. W. m 49 Haemoptysis 
non- Control group II - other. malignant diseases. 
C. V. 72 Ischaemic heart disease' 
B. H. F 48 Oesophageal stricture 
J. H. M 52 Myocardial infarction 
M. H. F 75 Myocardial infarction 
J. E. K. M 60 Myocardial infarction 
H. W. m 68 Cerebro. yascUlar-Ancident 
H. O. m 70 Cerebro vascular incident 
S. S. m 63 Cardiac failure 
J. W. M. 57 Glandular fever 
R. S. F 63 Hiatus hernia 
R. H. m 69 Hiatus hernia 
20-40/day 
6/day 
1 Ollay 
20/day 
Smoker 
Non smoker 
30/day 
20/day 
stopped in 
1975 
50/day 
1 O/day 
Non smoker 
. 
Non smoker 
Non smoker 
Non smoker 
Stopped 15 
yrs ago 
10/day 
5/day 
Non smoker 
20/day 
61 
Statistical analyses were carried out using an Olivetti P652 
computerised calculator and the significance, was determined using 
the students t-test. 
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2.3 ANALYTICAL METHODS 
2.3.1 Determination of vitamins A and E in the serum. 
Vitamins A and E were determined simultaneously by a 
modification of the fluorometric method of Hansen and Warwick 
(1969). They measured the fluorescence of vitamin A at an 
excitation' wave length of 340nm and an emission wave length 
of 480nm. However, there is considerable interference from 
carotenoids at this wave length (Thompson et al., 1973; 
Steveninck and de Goeii, 1973). Steveninck and'de'Goeii (1973) 
suggested the measurement of fluorescence at an emission wave 
length of 550nm, where interference from carotenoids is virtuallY 
zero. 
Th6 fluorescence was'accordingly'measured at'ýn emissio'n waveýý, 
length of 550nm., *-The intensity of fluorescence'increased linearly 
with concentration (Fig. 2.1) and there was no interference from 
c3rotenoids. 
Under the same conditions, vitamin E. exhibits fluorescence at 
an excitation wave Iength of 295nm and an emission wave'-length of 
340nm (Hansen and Warwick, 1969; Thompson et al. ', 1973). ý Vitamin E 
was 'determined simultaneously. The presence of vitamin A or other 
carotenoids has been shown not to interfere with the determination 
of vitamin E (Hansen and Warwick, 1969). The fluorescence of 
vitamin E increased linearly with concentration (Fig. 2.2). 
All-trans retinyl acetate (Sigma) in absolute ethanol was used 
as the standard for vitamin A. The absorbance of the working 
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standard solution (10pg/ml) was checked at 326nm using an SP 1806 
spectrophotometer before use (El% = 1550; Merck Index, 1968). lcm, ethanol 
DL-a-tocopherol (, Sigma) in ethanol was used as the standard for 
vitamin E and the ýbsorbance of the stock solution (100pg/ml) wa 
checked at 294nm before use (El% 71; Merck Index, 1968). lcm, ethanol 
All glassware used. was soaked overnight in 10% nitrid acid, washed 
several times with tap water and distilled water to remove any 
traces of detergent,. 
Aliquots (0.5ml) of serum were pipetted into 15ml. Sovril tubes 
fitted with teflon---lined caps. The same volume of water or standard 
was used instead of serum in the blank and standard respectively. 
Distilled water (lml) was added to each tube, mixed and 2ml of 
absolute ethanol was added slowly with mixing to precipitate proteins. 
Five millilitres of spectroscopic grade hexane (B. D. H) was then added; 
the tubes were capped and mixed for 30 seconds to ensure complete 
extraction of vitamin A from the aqueous ethanolic phase to the 
hexane layer. The tubes were then centrifuged at 1500 rpm'for'10 
min. in a Beckman J6 refrigerated centrifuge. 
The upper hexane layer was' separated and its fluorescence was 
measured using an MF3-Perkin Elmer fluorescence spectrophotometer. 
Recoveries of added vitamins A and E ranged from 95-100%. 
2.3.2. Determination of serum $-carotene. 
A spectrophotometric method was employed in the determination 
of a-carotene (Neeld and Pearson, 1963). 
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Fig. 2.1 Standard curve for the determination of vitamin A 
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Fiq. 2.2 Standard curve for the determination 
of vitamin E 
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The proteins were precipitated from the serum by adding 96% 
ethanol and o-carotene was extracted from the aqueous ethanol 
phase using petroleum ether (A. R). . The optical density of the 
petroleum ether layer was measured at 450nm using a Cecil 
spectrophotometer. All-trans $-carotene (Sigma) in petroleum 
ether was used to obtain a standard curve (Fig 2.3). 
2.3.3. Detemination of retinol-binding protein in the serum.. 
The single radial immunodiffusion technique (Mancini et al., 
1965) was used in the determination of retinol-binding protefil. 
LC-partigen immunodiffusion plates and stabilised standaýd 
human serum were obtained from Behring Diagnostics, Hoechst (U. K) 
Limited. An aliquot (2010) of the diluted test serum (1: 4) or 
standard serum was placed in each well in the immunodiffusion 
plate. At least three different dilutions of standard serum were 
placed on each plate. The plates Were closed and incubated for 
48 hours at room temperature. The diameters of the precipitin 
rings were measured using a calibrated lens against a dark 
background. The concentrations of retinol-binding protein in the 
test sera were obtained from a standard curve of the square of the 
diameter of the precipitin ring against concentration (Fig. 2-4). 
2.3.4. Determination of prealbumin in the serum. 
The concentration of prealbumin in the serum was determined by 
single radial immunodiffusion technique (Mancini et al., 1965). 
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Fig. 2.3 Standard curve for the determination 
of a-carotene 
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Fig. 2.4 Standard curve for the determination of 
retinol-binding'protein 
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A gram of agarose (Mercia Brocades Limited) was mixed with 
0.024 M barbitone buffer, pH 8.6 and heated gently with constant 
stirring, until the agarose had completely dissolved. An 
aliquot (10ml) of roolten agarose was transferred to a large pyrex 
tube and placed in a water bath maintained at 550C for 5-10 min. 
One hundred microlitres of rabbit antiserum against human 
prealbumin (Hoechst (U. K) Limited) was added to the molten agarose, 
mixed gently and allowed to stand at 55 0C for 5 miný" The molten 
agarose containing antiserum was poured uniformly on a warm glass 
plate (8.2 x 8.2cm) kept on a balanced table and allowed to 
Wells were cut in the agarose when it had set using a gel-puncher 
and a punching template. An aliquot (3pl) of diluted serum (1: 4) 
or stabilised standard serum (Hoechst (U. K) Limited) in varying 
dilutions was placed in each well. The plates were incubated for 
48 hours in moistened, air tight plastic boxes at room temperature.. 
After diffusion was complete, the gel was pressed to remove 
any precipitatea proteins. It was then dried -; n a curren-ý of warm 
air and stained by immersing the plate in Coomassie brilliant blue 
stainer for 2-3 min. The background colour was wash ed off bY 
immersing the plate in ethanol-acetic acid destainer. The plate 
was dried in a current of warm air and the diameters of precipitin 
rings were measured using a cal. ibrated., lens, Prealbumin, 
concentrations of test sera were obtained from a plot of the square 
of the diameter of the precipitin rings against concentration of 
stabilised sera (Fig. 2.5). 
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Fig. 2.5. Standard curve for the determination of prealbumin 
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2.3.5. Determination of proteins in the serum. 
Total proteins were determined colorimetrically using the 
Biuret reagent (Sigma). 
Total globulins were measured by the intensity of the colour 
given with the glyoxylic acid reagent (Sigma). 
The albumin concentration was obtained from the difference 
between total protein and total globulin concentrations. Standard 
curves were plotted (Figs 2.6 and 2.7) using a standard protein 
solution (Sigma) containing human albumin (5g/100ml) and human 
globulin (3g/100ml). - 
2.3.6. Determination of 11- 
the serum. -! 
ýZdroxycorticosteroid levelý in 
The glucocorticoids in the serum were measured as 
I 11-hydroxycorticosteroids. Mattingly's method (1962) was 
-, 
em , ploYed 
for the determination of 11-hydroxycorticosteroids. Corticosteroids 
were extracted from the serum with methylene chloride and the 
fluorescence obtained by treatment with ethanol-sulphuric acid 
reagent was measured. 
To an aliquot (0.2ml) of serum'in a 10ml Sovril tube, lml of 
I 
water and 4ml chloride (B. D. H, Spectroscopic grade) was added. 
Corticosteroids were extracted into methylene chloride by gentle 
mixing in a rotatory mixer for 20 minutes. A reagent blank and a 
standard containing water and cortisol (Sigma) respectively were 
carried through the procedure. The tubes-were centrifuged and the 
top aqueous layer was removed, by suction- 
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Fig 2.6 Standard curve for the determination of total protein 
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An aliquot (3ml) of the methylene chloride extract was 
transferred to a 10ml graduated tube. The fluorescence of six 
extracts of serum, blank and standard, were carried through the 
procedure on each occasion. At zero time, the fluorescence 
reagent (containing 7 volumes of sulphuric acid and 3 volumes of 
ethanol) was added to the blank and mixed vigorously for 20 seconds. 
This procedure was repeated by adding the fluorescence reagent at 
one minute intervals. The methylene chloride layer was sucked off 
from each tube in turn, starting with the blank. The fluorescence 
of each solution was-measured atexactly'15 minutes after mixing 
the fluorescence reagent, using an MF3-Perkin Elmer fluorescence 
spectrophotometer, at. an excitation wave length of 475nm and an 
emission wave length of 530nm. The standard curve obtained is 
shown in Fig. 2.8. 
2.3.7. Determination of zinc and copper in the serum. 
Zinc and copper concentrations in the serum were measured by - 
atomic absorption spectrophotometry. Serum was diluted I in-5 
with distilled water to avoid interference of the atomic absorption- 
signal by the serum matrix. Zinc acetate (O. lmM) and cupric 
chloride (O. lmM)'were used as the respective standards for zinc and 
copper and standard curves were plotted (Figs. 2.9 and 2.10). The 
following settings were used on, IL 353 atomic absorption 
spectrophotometer 
Zinc Copper 
Wave length 213.9nm 324.7nm 
Slit width 320pm 3201im 
Lamp current 5 mA 5 mA 
Voltage 530 V 530 V 
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Fig. 2.8 Standard curve for the determination of 
11-hydroxy corticosteroids 
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Fig 2.9 Standard curve for the determination of zinc 
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2.4 RESULTS 
The vitamin A concentration in the serum of lung cancer 
patients was significantly (p < 0.01) lower (Table 2.3) than 
that of control group I (non-malignant lung diseases) and 
control group II (other non-malignant diseases). The 
concentrations of vitamins A and E and ý-carotene were similar 
in the two control groups. The a-carotene concentration tended 
to be somewhat lower in lung cancer patients (105 1 9.3 pgllOOml) 
as compared to both control groups, but the difference was not 
significant (Table 2.3). The-vitamin E concentration in the 
serum was similar in lung cancer patients and both control groups 
(Table 2.3). 
Only two lung cancer patients had vitamin A values above the 
means of the two control groups (Fig. 2.11). Patients having 
other non-malignant diseases (control group II) had the highest 
mean value for vitamin A (61.9 t 2.2 jig/100ml), while patients with 
non-malignant lung diseases (control group I) had a mean vitamin A 
concentration of 58.3 
t 1.5 li'g/100ml. Four patients with advanced 
malignant disease had a vitamin A concentration of less than 
30pg/lOOM1. Patients with squamous cell carcinoma (mean value - 
46.4 vg/100ml) and undifferentiated carcinoma (mean value - 43.4 pg/100ml) 
had slightly lower mean vitamin A levels than those with oat cell - 
carcinoma (50.5 vg/100ml), but, 4Che difference was not significant 
(Fig. 2.11). 
A significantly (p < 0.001) lower concentration of retinol- 
binding protein was also observed in the serum of lung cancer patients 
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as compared to both control groups. (Fig. 2.12). Lung canc; r 
patients had a mean retinol-binding protein concentration of 
4.1 t 0.23 mg/100ml, while patients having non-malignant lung 
diseases (control 6roup I) had a mean retinol-binding protein 
concentration of 5.38 t 0.15 mg/100ml and those having other 
non-malignant diseases (control group II) had a mean Value of 
5.47 t 0.27 mg/100ml. 
Furthermore, serum vitamin A showed a highly significant 
positive correlation with retinol-binding protein (r -: 0.. 86, . 
< 0.001) in lung cancer patients, but not in the control groups 
(Fig. 2.13). 9 
The concentration of prealbumin in the serum of lung cancer 
patients was not significantly different from that of either of 
the two control groups (Fig. 2.14). Lung cancer patients had a 
mean prealbumin concentration of 20.8 t 1.7 mg/100ml, as compared 
to control group I, which had a mean prealbumin level of' 
23.9't 1.6 mg/100ml, and control group II with a mean value of 
25.0 t 1.5 mg/100ml. 
HoweversJour patients who'had very low values for vitamin-A3, 
had low values for retinol-binding protein and prealbumin as well. 
Three of these four patients (G. R., A. H. and F. C. ) died within a 
0 FCUCAgnosis. 
shorý period,, The lung cancer patient with the highest value of 
vitamin A (F. L. ) had a family history of lung cancer. 
The mean concentration of 11-hydroxycorticosteroids in lung 
cancer patients was not significantly different from that of the 
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two control groups (Table 2.4). 
Lung cancer pýtients had lower serum zinc levels when 
compared to both control groups and the difference was significartt 
(p < 0.05) when lung cancer patients were compared with control 
group II (Table 2.4). The mean concentration of copper in the 
serum of lung cancer patients was higher (p < 0.05) than that of 
control group I (Table 2.4). The differences between the 
concentrations in the cancer patients and those in the other 
control group were in the same direction, but not significant. 
As a result of these differences, the zinc copper ratio in cancer 
patients was significantly (p < 0.01) lower than in either of-the 
two control groups (Table 2.4). 
The serum zinc concentrations showed a significant-positive 
correlation (r 0.55, p<0.01) with the concentration of serum 
vitamin A (Fig. 2.15). A highly significant positive correlation 
(r = 0.55, p<0.01) also existed between zinc and retinol-binding 
protein in the serum (Fig. 2.16). 
The total protein, albumin and globulin levels were similar 
in the lung cancer patients and control groups (Table 2.5). 
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2.5. 
- 
DISCUSSION 
Significantly lower vitamin A concentrations were. found in 
the serum of lung cýncer patients, as compared to control groups -. 
having either non-malignant lung diseases or other non-malignant 
diseases. These findings are in agreement with the earlier 
observation of Basu et al. (1976). However, the present findings 
differ from those of Cohen and co-workers (1977), who studied the 
dietary vitamin A intake and serum vitamin A in non-resectable lung 
cancer patients. The mean value of vitamin A in the control groups 
of the present study is 60pg/lOomi, which is somewhat higher than 
the mean control value of 50pg/loomi, quoted by Cohen et al. 
Moreover, these workers quoted a value for a control population.,, 
They did not, in fact, -determine the control value in an age-matched 
population. The mean values in their patients tended to, be somewhat 
higher than the values, obtained in the present study. -" 11 ., I 
The finding,, of, lower concentrations of vitamin A in the serum-of-, 
these patients may suggest a Possible role of this vitamin-in. the-, 
aetiology oflung cancer, as has been noted in experimental, animals 
(Nettesheim, nd Wil, liams, -, 
1976; Nutr. Rev., 1979). However,, the 
importance of vitamin A as an aetiological factor in, human, lung cancer 
is not at present clear. 
Cigarette smoking is an important contributory factor in the 
causation. of lung cancer (Doll and Peto, 1976). It is-possible 
that the, carcinogenic, polycyclic hydrocarbons present in-cigarette 
smoke may affect the plasma vitamin A by depleting body stores of-, 
this-vitamin.. In fact, an early study showed that1arge'doses of 
intra-peritoneally administered 3,4. benzo(a)pyrene and 
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3-methyl cholanthrene results in a marked reduction in hepatic 
vitamin A in'the rat. (parruthers, 1942). Recently Mettlin and 
-co-workers 
(1979) have reported that high dietary vitamin'A intake 
reduces the risk of development of lung cancer in smokers, 
particularly in heavy-smokers. However, the present study did 
not reveal an association between serum vitamin A and smoking habits 
in lung cancer patients. This may be due to the difficulties 
encountered in obtaining accurate smoking histories from patients', 
in view of the variability of smoking habits over a. period of time. 
The concentration of 11-hydroxycorticosteroids in the serum 
of lung cancer patients was not significantly different. from that 
of the controls. Thus there was no evidence in these patients to 
support the suggestion of Cristaelis and co-workers (1976) that 
elevated glucocorticoids-were responsible for the low vitamin A 
levels observed in lung cancer patients. However, glucocorticoids 
may be an important contributory factor in depressing vitamin A in 
patients having lung turrours with Pctopic production'of ACTH. *This 
is frequently observed in oat-cell carcinoma of the lung (Omenn and 
Wilkins, 1970; Nathanson and Hall, 1974). Only a few patients' -, 
with oat cell carcinoma were included in the present study. The 
effect of corticosteroids (glucocorticoids) on vitamin A was studied 
experimentally in rats and the results are presented in Chapter Three. 
Serum vitamin A levels may be affected by impaired fat 
absorption. However the serum concentration of vitamin E, another 
fat-soluble vitamin was unaltered in lung cancer patients. Also, 
$-carotene levels in the'serum of lung cancer patients were not 
90 
significantly different from that of controls. Therefores it 
is. unlikely that, serum vitamin A is decreased due to malabsorption 
of fat. - Vitamin E is also important in the absorption and 
biological ytilisaiion of vitamin A (Ames, 1969; Jagadeesan and 
Reddy, 1978). The lack of correlation between serum vitamins A and 
E suggests, that decreased vitamin A is not a manifestAtion-of 
vitamin E deficiency. 
Vitamin A is transported to the target tissues bound to 
retinol -binding. protein (Kanai Et. al . 1968). The observation of markedly 
decreaýed serum r6tinol-binding protein al. ong with. low serum 
vitamin,. A raises., the interesting possibility that decreased , 
vitamin A may be the result of a lower concentration of carrier 
protein. . 
Furthermore, a highly significant correlation between 
serum vitamin A-and retinol-binding protein was observed in lung,, 
cancer patients, but not in controls. Thus, it is possible that, 
the delivery of vitamin A to the tissues is determined, by the 
availability of the carrier protein in. lung cancer patients. .,. 
, 
Vitamin A bound to retinol-binding protein nomally. circulates 
as a biprotein- complex with prealbumin (Raz et al., 1970; Peterson, 
1971ý. Prealbumin. is also involved in the transport of thyroxine, 
but the two mechanisms are not inter-dependent (Raz and Goodman, 
1969). The observation of similar values for the concentration of 
prealbumin in both lung cancer patients and controls,, ' suggests, that. 
decreased circulating vitamin A and retinol-binding protein did not 
result from a deficiency of prealbumin. 
The concentration of circulating retinol-binding protein, and 
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prealbumin is very sensitive to the nutritional status of the 
individual (Ingenbleek et al., 1972; Ingenbleek et al., 1975a). 
Several workers have'demonstrated a decrease in vitamin A and 
retinol-binding prqtein in children with protein-calorie 
malnutrition (Smith et al., 1973b; Ingenbleek et al., 1975b). 
Moreover, supplying calories and protein ýiithout supplemental 
vitamin-A resulted in a clinical cure and. a'significant rise in 
vitamin A, retinol-binding protein and prealbumin (Smith et al., 
103b). 
Malnutrition is often . se - en in patients with -advanced 
malignant disease (Theologides, 1977; Leading article, British 
Medical Journal, *1979), although it is less common in malignant 
disease of the lung (Dickerson and Basu, 1978). Therefore, it 
is possible I that the"decreased vit I amin A and retinol-b6ding protein 
was a manifestation of generalized nutritional deficiency. However$ 
the 'observation of similar"values for prealbumiin in lung'cancer _- 
patiýnts and controls excludes tkis possibillitý. This-is further 
supported by the fact that total protein and albumin concentrations were 
similar in lung cancer patients and controls. These results 
suggest that the observed low values are a specific effect on 
vitamin A and retinol-binding protein in. lurig cancer patients rdther 
than a generalized nutritional deficiency. 
Smith and co-workers (1974) suggested that zinc may'be - involved 
in the mobilisation of vitamin*A from the liver. Zinc-deficient' 
rats had low plasma vitamin A levels, while accumulating vitamin A 
in -the -liver (Smith'et al., 1973c) Moreover, a markedly lower 
concentration of plasma retinol-binding protein has been reported in 
li: 
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zinc-deficient rats, as compared to zinc-sufficient rats fed 
ad libitum or pair-fed with zinc-deficient rats (Smith et al., 1974). 
_. 
Furthermore, the liver concentration of retinol-bindi*ng protein 
in zinc-deficient, rats was only, 55 60% of that of ad libitum oF, 
pair-fed. controls. This data suggests that zinc deficiency 
probably interferes with the synthesis of, retinol-binding. protein. 
Repletion of zinc-deficient animals restored the plasma vitamin A 
concentration to values within the normal, range, after. three days 
of treatment (Brown et al.,, 1976). Mobilisation of vitamin A by 
intra-peritoneal administration of large doses of zinc sulphate has 
also. been observed, in normal male weanling rats (Ette et'al.,, 1979). 
., -In, 
the present study, low, vitamin A levels were associated 
with, subnormal serum zinc levels. Other, workers have also observed 
decreased blood and plasma zinc concentrations in patients, with, 
lung cancer (Davies et al., 1968; Morgan, 1970; Davies, 1972)., The 
observed., elevation of serum copper concentrations could. hav-e been, due 
to an increase in the concentration of the carrier protein 
ceruloplasmin. - Evidence in support of this suggestion was obtained 
by Mateo et al. (1979) who reported elevated serum copper levels 
which were significantly correlated with elevated serum ceruloplasmin 
levels. The serum zinc levels were significantly correlated with 
both vitamin A and retinol-binding protein in the serum. Therefore, ' 
it is possible that the decreased zinc in some way contributed to 
the decrease in ci'rculating retinol-binding protein and vitamin A. 
Deficiency of zinc associated with decreased vitamin A, has also been 
observed in the plasma of patients with alcoholic cirrhosis (Smith 
et al., 1975b)and cystic fibrosis (Jacob and Sandstead, 1978). 
so -'Michaelsson et al. (1977) have also observed significantly lower 
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concentrations of zinc and retinol-binding protein in the serum of 
male subjects with severe acne. 
Zinc plays an_important role in the synthesis of nucleic acids 
and proteins and is a constituent of thymidine kinase and 
DNA-dependent DNA and RNA polymerases (Vallee, 1977). Zinc is 
also required in certain steps of the cell multiplication cycle 
(Riordan, 1976). Thus, it is*not surprising that zinc deprivation 
inhibits the growth of Walker-256 carcinosarcoma (De Wys et al,., 1970). 
some leukaemias and Lewis lung carcinoma (Pories et al., 1978) in-mice, 
a'nd results in increased survival. Furthermore, human malignant 
lung and breast tissues have been found to contain significantly 
higher concentrations of zinc when compared to the normal non- 
cancerous tissue (Mulay et al., 1971; Schwartz et al.,, 1974). 
Therefore, it is tempting to suggest that the increased requirement 
for zinc during growth of the tumour may contribute at lea st in part 
to the decrease in circulating retinol-binding protein and vitamin A. 
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CHAPTER THREE 
EFFECT OF CORTICOSTERONE ON THE 
VITAMIN A STATUS OFRATS, 
T. 
95 
3.1 INTRODUCTION 
Increased ACTH secretion with excessive glucocorticoid 
production has been. observed in some lung tumours, particularly 
the oat cell type (Marks, 1961; Nathanson and Hall, 1974). 
Adrenal hypertrophy with excessive secretion of glucocorticoids 
has also been observed in animals subjected to various types of 
stress, such as skin grafts, inoculation with tumour cells or 
physical stress (Seifter et al., 1976). Experimental studies 
have revealed that physical stress by partial body casting 
precipitates frank-vitamin A deficiency in rats on a marginal-. * 
intake of the vitamin (Seifter et al., 1973a). It is possible 
that stress-induced secretion of glucocorticoids antagonise tissue 
vitamin A by favouring its elimination from the body. Thus, an 
earlier study showed that administration of cortisone to rats over 
a long period resulted in loss of'vitamin A from the liver and 
kidney (Clark and Colburn, 1955). 
A relationship between vitamin A metabolism and corticosteroids 
(glucocorticoids) is further indicated by the fact that the vitamin 
antagonises the immune-suppressive effects of hydrocortisone in mice 
(Cohen and Cohen, 1973). Moreover, it prevents the development of 
steroid-induced ulcers in experimental animals (Hutcher et al., 1971) 
and reverses the inhibition of wound healing caused by glucocorticoids 
(Stephens et al ., 1971 ; Ehrl ich et al.. , 1973). 
The present study was undertaken to ascertain if exogenous 
glucocorticoids antagonise vitamin A by lowering its tissue 
concentration. The effect of corticosterone on the levels of 
vitamin A in the plasma and various tissues of normal healthy rats 
96 
was studied. The plasma levels of vitamin E, another fat- 
soluble vitamin was also. studied to determine whether the effect 
was specific to vitamin A. 
:. 
'T: 
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3.2 EXPERIMENTAL PROTOCOL 
Adult male Wistar-Albino rats, weighing approximately 200g 
were used and maintained on a stock pellet diet (Spiller) and 
water ad libitum. -The animals were kept in individual cages 
for two days prior-to treatment to acclimatise them to their 
environment. 
Effect of corticosterone treatment for different 
intervals of time. 
The animals were treated with corticosterone (25mg/kg body 
weight) subcutaneously, twice daily and killed at 0,1,3 and 4 
days following treatment. Blood was collected by cardiac puncture 
into heparinised tubes. The liver, thymus and adrenal glands I 
were taken from each group of 5 animals. The separated plasma 
and weighed tissues were stored at -40 
0C until analysed. 
3.2.2. Effect of treatment with corticosterone and retinol 
for one week. 
Twenty-four rats were divided into 4 groups. Group A was 
given propylene glycol subcutaneously, twice daily and corn oil 
intraperitoneally, once daily and served as controls. Group B 
was treated with corticosterone in propylene glycol (15mg/kg 
body weight, subcutaneously twice daily) and corn oil intraperitoneally. 
Group C was treated with retinol in corn oil (3000 IU per animal, 
intraperitoneally, once daily) in addition to corticosterone. Group D 
was given retinol (3000 IU, intraperitoneally, once daily) and 
98 
propylene glycol. 
All animals were treated for 7 successive days and killed on 
the 8th day and blood and organs were collected as described in the 
previous study (3.2.1). 
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3.3 ANALYTICAL METHODS 
The concentrations of vitamins A and E in the plasma were 
determined by the fluorometric method described earlier for the 
serum (Chapter Two). 
3.3.1 Determination of vitamin A in tissues. - 
The'vitamin A content of tissues was determined fluorometrically 
(Thompson et al., 1971). A weighed amount of tissue (0.1 - 0.5g) was 
saponified by heating in a boiling water bath for 15 minutes with 
60% aqueous potassium hydroxide (0.5ml) in the presence of 1%'ethanolic 
pyrogallol (1 ml). The tubes were then'cooled and 1 ml of water 
was added. The unsaponifiable matter was extracted with hexane and 
its fluorescence was measured as described for the serum (Chapter Two). 
In the determination ofevitamin A content of the liver, about 
0.1 g of tissue was used and the extraction was carried out with two 
5 ml aliquots of hexane. ' The fluorescence of the pooled extracts 
was measured. The standard curve is shown in Fig. 3.1. 
a 
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Fig. 3.1 Standard curve for the determination ofitissue vitamin Af 
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3.4 RESULTS. 
3.4.1 Effect of corticosterone treatment for different 
intervals of time. 
The body weigk Of the animals treated with corticosterone 
(25mg/kg, twice daily) remained more or less unchanged after the 
4 day treatment (Table 3.1)., The restriction of body weight 
gain was not due to decreased food intake. The absolute liver 
weights of steroid-treated animals increased slightly on the. first 
day and decreased to its normal value on further treatment (Table. 3.1). 
The liver weight relaýive to body weight showed a similar variation, 
increasing significantly (p < 0.05) on the first day and returning 
to normal values on further treatment (Fig.. 3.2). 
Both the absolute and relative weights of adrenals decreased 
gradually and the decrease was significant (p < 0.05) only after 
three days of corticosterone administration. Significant (p < 0.01) 
thymic involution occurred even after treatment with corticosterone 
for one day, and further treatment resulted in a gradual decrease in 
weight of the thymus (Table 3.1). The thymus weight relative to 
body weight was also markedly decreased on steroid administration 
(Fig. 3.2). 
The concentrations of plasma vitamins A and E in animals 
receiving corticosterone for various periods are shown in Table 3.2. 
The plasma concentration of vitamin A decreased signific antly (p < 0.05) 
after 3 days of treatment, while the plasma vitamin E levels fell 
significantly (p < 0.05) only after 4 days. The liver vitamin A 
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concentration was' more sensitive to corticosterone treatment, 
decreasing significantly (p < 0.05) even after one day. (Table 3.2). 
The total hepatic content of vitamin A also showed a gradual 
decrease on steroid administration. 
The amount of vitamin A in the adrenal glands showed a gradual 
fall, and it was significant: from day 3 of treatment (Fig. 3.3). 
The vitamin A content of the thymus, however, decreased significantly 
(p < 0.01) even after administration of corticosterone for one day. 
Further treatment resulted in a gradual-depletion of vitamin A from 
the thymus (Fig. 3.3). 
3.4.2 Effect of treatment with corticosterone and retinol 
for one week. 
Treatment with corticosterone (15mg/kg, twice daily) for one 
week caused a marked reduction in body weight gain (Table'3.3) which 
remained unchanged even when the steroid was administered in 
combination wita retinol(', ')000 IU). Corticosterone did not afFect 
anci cwtecorAcrone- 
the weight of the liver, while retinol. caused a slight increase in 
liver weight relative to body weight (Table 3.3). In the 
corticosterone-treated animals, there was a decrease of about 70% in 
absolute thymus weight when compared with the control animals 
(Table 3.3). Like the liver, the absolute weight of the thymuss 
remained unchanged even when the steroid was administered concomitantly 
with retinol. Also, it was noted that the animals treated with retinol 
alone had a thymus weight similar to the controls. The thymus weight 
relative to body weight was slightly elevated in retinol-treated 
animals, but the increase was not significant. The weight of adrenal 
glands was. also, decreased with corticosterone'and simultaneous 
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Each value is the mean t SEM for 5 rats. 
Significantly different from control. p<0.05, ** p<0.01, 
*** p<0.001) 
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treatment with retinol did not alter the weight loss. 
The plasma concentration of vitamin A fell significantly 
(p < 0.01) in anima: ls treated with corticosterone alone, but not 
in those treated with the steroid in combination with retinol 
(Table 3.4). The vitamin E concentration also fell (p < 0.05) on 
steroid-trea-tment, -but to a lesser extent. The plasma levels of 
vitamin E were restored to control values by concomitant retinol 
t reatment. , The vitamin A contents of the liver and adrenal'glands. 
fell significantly on corticosterone treatment and-rose to control 
values in animals treated with corticosterone in combi'nation with - 
retinol. Retinol treatment alone increased the vitamin A contents 
of the liver'and adrenal glands to values much higher than the 
controls. 
The loss of vitamin A resulting from the administration of 
corticosterone was most marked (p < 0.001) in the thymus. (Table 3.4). 
Concomitant administration of retinol increased the vitamin A 
content oF the thyrrus to 'values significantly (p < 0.001) hicher than 
the controls. A marked increase (p < 0.001) in vitamin A content 
of the thymus was also noted in animals treated with retinol alone, 
but the values were similar to those found in animals treated with the 
vitamin in combination with corticosterone. 
Histological studies of the thymus revealed focal necrosis 
affecting the thymocytes of the cortical region in corticosterone- 
treated animals. These changes were not observed in animals treated 
with both corticosterone and retinol, or in the group given retinol 
alone or in the control groups. 
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3.5 DISCUSSION 
Pretreatment 6`f normal rats with corticosterone (25mg/kg, 
twice daily) for-four successive days resulted in a significant 
reduction in vitamin A status, as determined by decreases in the 
vitamin A levels in plasma, liver and adrenal glands. Th e 
corticosterone-me late epression of the vitamin A content of 
the adrenals appeared parallel to the weight loss of the glands. . 
The observed decrease in size of the adrenals may be due to a feed- 
back mechanism resulting from a decreased necessity for 
corticosteroid production, in the presence of exogenous corticosteroids. 
Of the tissues studied, thymus was the most sensitive to 
corticosterone treatment. Thus, steroid treatment for one day or 
more-resulted in significant thymic involution and marked loss of 
vitamin A. It is noteworthy that loss of vitamin A from the plasma, 
adrenal glands and thymus has also been reported in mice subjected to 
physical stress by the application of a partial body cast to the 
thorax for 3 days (Rettura et al., 1976). In this study the greatest 
loss, of vitamin A was from the thymus. 
- The corticosterone-mediated depression of vitamin A in the plasma, 
liver and adrenals was restored to normal levels by concomitant retinol 
administration. Steroid-treatment also decreased the plasma 
concentr ation of vitamin E. The ability of retinol to restore the 
depressed-plasma vitamin E levels suggest a'synergistic effect between 
the two vitamins as suggested by Bauernfeind et al. (1974). 
However, upon administration of corticosterone in combination , 
ill 
with retinol, the most profound effect was seen in the thymus; for 
the vitamin A content rose to values about three times higher than 
the controls, wi thout any significant increase in the size-of the 
organ. It is also of interest that corticosterone-induced focal 
necrosis of the thymocytes in the cortical region was prevented by 
concomitant retinol administration. Thus, the thymus has the 
ability to accumulate vitamin A, even when involuted as a result of 
exo6enous corticosteroid action. This seems to suggest a greatly 
increased requirement of the thymus for vit amin A. 
An impoftant function of the thymus is its involvement in. 
immune reactions, particularly cell-mediated immunity. Seifter 
et al. (1973b) have shown. that physical stress by partial body casting 
enhanced the development of tumours in mice inoculated with Moloney 
sarcoma virus. An associated decrease in weight of the thymus was. 
observed, due mainlyto loss of cortical cells. High. doses of 
vitamin A decreased the incidence and severity of development of the 
viral sarcoma (Seifter et al., 1973c) and also of a transplantable 
melanoma (Felix et al., 1975) in mice. Furthermore, vitamin A 
administration reduced the incidence of viral tumours-during 
immunosuppressive chemotherapy in transplantation and accelerated 
graft rejection (Rettura et al., 1975). The increased incidence of 
tumours may be due to reduced immunocompetence. In fact, Zisblatt 
and Lilly (1972) showed that animals with reduced immunocompetence 
had a markedly higher susceptibility to tumour induction. Therefore, 
it seems likely that the ability of vitamin A to restore 
4 
immunocompetence under conditions associated with increased 
corticosteroid production is mediated by. the thymus. 
Recent work suggests that vitamin A stimulates both humoral and 
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cell-mediated immunity. Jurin and Tannock (1972) observed that 
intra-peritoneal injection of vitamin A accelerated the rejection 
of male skin grafts by isologous female recipient mice. An 
immune stimulating. effect of vitamin A therapy has also been 
observed in childrdn with Down's syndrome (Palmer, 1977). 
It is possible that low vitamin A may favour tum6ur growth by 
compromising immune reactions which normally deal with a small number 
of transformed cells. Therefore, it is not surprising that several 
indices of immunological competence are impaired in pati ents with - 
malignancies, particularly in the lung (Israel, 1973; Botton et al., 
1975; Holmes, 1976). As described earlier (Chapter Two), serum 
vitamin A levels are decreased in patients with lung cancer. The 
present study suggests that elevated gl, 4cocorticoids may be a 
contributory factor in lowering vitamin A in lung cancer patients, 
particularly in oat. cell carcinomas which may-'be-z- associated with 
ectopic ACTH production. The failure to find this correlation in 
our patients could have been due to the fact that only five patients 
with oat cell carcinoma, were sttidied. 
There has been a recent claim that treatment with vitamin A 
(retinyl palmitate) or a synthetic analogue (13-cis retinoic acid) 
stimulated the immune response in lung cancer patients and reduced 
tumour progression (Micksche et al., 1977). However, the results 
were not very clear cut possibly due to the rather advanced nature 
of the disease. Therefore, it seems reasonable to suggest that the 
decreased vitamin A levels in lung cancer patients may in turn 
affect tumour growth by impairing cell-mediated immunity. 
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CHAPTER FOUR 
VITAMIN A AND METASTATIC TESTICULAR 
TERATOMA IN MAN 
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4.1 INTRODUCTION 
Abnormalities in. vitamin A metabolism have been observed in 
patients with primary lung cancer (see Chapter Two), and may also 
occur in patients with other primary malignant tumours which give 
rise to metastases in the lung. Testicular teratoma is a highly 
malignant tumour which occurs in younger rather than older men and 
,, ýnýZdly spreads to the lung in most cases. It seemed to be of 
interest to study the vitamin A transport system and other rela. ted 
factors, in such patients. 
Moreover, aggressive chemotherapy used in the treatment of 
advanced testicular teratoma often has undesirable side effects 
(Editorial, Cancer Topics, 1979). In fact, toxicity may limit the 
amount of drugs which can be given to achieve significant remission. 
Furthermore, treatment, with antineoplastic agents aggravates 
deficiencies of cancer patients who are already nutritionally 
compromised (Donaldson, 1977; Ohnuma and Holland, 1977; Donalds. on and 
Lenon, 1979). 
Two chemotherapeutic regimens currently employed in the treatment 
of metastatic testicular teratoma are: 
I., Combination chemotherapy with vinblastine and 
bleomycin (Samuels et al., 1976). 
2. Combination chemotherapy with cis-diamine dichloro 
platinum (II) - cis'-DDP, vinblastine and bldomycin 
(Einhorn and Donohue, 1977). 
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The major toxic manifestations of vinblastine are, in dec. reasing 
order of frequency, leucopaenia, nausea, vomiting and anorexia, 
neurotoxicity and hair loss, and stomatitis, diarrhoea, constipation, 
lethargy and depression (Creasy, 1975). The organs more susceptibie 
to the toxic side effects of bleomycin are the skin, lungs and mucous 
membranes, (Bennet and Reich, 1979). Drug-induced pyrexia and 
nausea and vomiting are frequently observed (Blum et al., 1973) and the 
incidence, of stomatitis is increased when it is*combined with other 
antineoplastic agents, such as cis-DDP (Kaplan and Vogl,, 1978). The 
major toxic effects of cis-DDP include gastro-intestinal, audiologicals 
renal and haematological manifestations, (Rozencwig et al., 1978). 
Thus, nutritional disturbances may also occur in patients r eceiving a 
combination of these drugs. Samuels and co-workers (1976) have 
observed a marked loss in body weight during chemotherapy with 
vinblastine and bleomycin. 
No studies have so far. been conducted to investigate the effects 
of these drugs on vitamin status. In the present study, the plasma 
level of vitamin A and other parameters. which may affect its 
concentration in the plasma were studied in patients with metastatic 
testicular teratoma and the values, compared with those of normal 
healthy subjects, to ascertain whether abnormalities in vitamin A 
metabolism also exist in these patients at the onset of treatment. 
The variation of plasma vitamin A and related factors was followed 
during chemotherapy. and compared with that of thiamine, pyrido xine 
and ascorbic acid. 
p 
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4.2 PATIENTS 
Nineteen patients with metastatic testicular teratoma admittect 
to the Royal Marsden Hospital, Sutton, Surrey were studied. - Their 
ages ranged from 19 to 52 years with a mean age of 29.6. 
+ 2.0 years 
(Table 4.1). The tumours were classified according to their 
histology and staging (Peckham et al., 1979). The histological 
classification of the tumours is shown in Table 4.1, together with an 
abbreviated clinical description. The details of clinical staging* 
as, described by tumour extents, site(s) and volume are as follow s: 
Stage I- Lymphogram negative, no evidence of 
metastases. 
Stage II Lymphogram positive, metastases confined 
to abdominal nodes, 3 sub-groups recognised: 
A- maximum diameter of metastases < 2cm; 
B- maximum diameter of metastases 2-5 cm; 
II maximum diameter of metastases > 5cm. 
Stage III - Involvement of supradiaphragmatic and 
infradiaphragmatic lymph-nodes. 
No extralymphatic metastases. 
Abdominal status: A, B'S C as for Stage 
.. Stage IV - Extralymphatic metastases. 
Suffixes: 0-lymphogram negative; A, B, C 
as for Stage II. 
Lung status: 
LI<3 metastases; 
L2 multiple < 2cm maximum diameter 
L3 multiple > 2cm diameter 
I 
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Liver status: 
H+ liver involvement 
t'plasma vitamin A levels and some related The preteatmen 
factors found in these patients were compared with thOsb Of 8 normal 
healthy male subjects (controls). The ages of the controls. ranged 
from 19 to 34 years, with a mean value of 24.1 ± 2.2 years. 
Of the 19 patients, it was possible to follow longitudinally, ' 
7 patients being treated on the Samuels- regimen and 7 patients being 
treated on the Einhorn regimen. 
Samuels regimen: Each patient received at least four courses of 
therapy' (with a maximum of six) at intervals of 4-5 weeks. The 
2 
patients received vinblastine (15mg/m s intravenously o6 days 1 and 2) 
and bleomycin (30mg/day, administered as a continuous' infusion over 
2A hours on days 1 to 5). . Overnight fasting blood samples were 
collected before starting treatment and on day 7 of each course. 
0 
Einhorn regimen: Each patient was given four courses of therapy, 
the duration of each course being 21 days. The patients received 
2 
cis-DDP (20mg/m , intravenously, on days 1 to 5), vinblastine 
(0.2mg/-kg,, intravenously, on days 1 and 2) and bleomycin (30mg/dayS 
intravenously, on days 2,9 and 16). Blood samples were collected 
before treatment, on day 7 (before discharge. from hospital) and on 
day 16. 
The response to therapy in the patients studied longitudinally 
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Table 4.1 Clinical details of patients with testicular teratoma. 
Name Age 
(years) 
Previous 
treatment 
Histologicala and clinical 
staging of the tumour 
G. T. W 34 Right orchidectomy MTU, Stage IVC H+ 
J. C. 42 Right orchidectomy MTI,, Stage IVO L3 
and radiotherapy . 
M. M., 
. 
25 Right orchidectomy MTI, Stage IVC L2 
W. P. 22 Left orchidectomy, MTU, Stage IIC. , 
nephrectomy, 
ureterectomy and 
radiotherapy 
N. W. 28 Left orchidectomy MTU, Stage IVO' L2 
A. G. 34 Left orchidectomy MTUIý Stage IIIB,., 
and radiotherapy 
M. H. 33 Right orchidectomy MTU, Stage IIC 
G. S. 23 Richt orchidectomy MTUs Stage IVC H+ 
G. S. 38 Right orchidectomy MTIS, Stage IVO L2 
and radiotherapy _ 
D. M. 27 Right orchidectomy MTU, Stage IVA L 
and radiotherapy 
P. D. 22 Left orchidectomy MTI, Staje 1VO L 
and radiotherapy 
A. S. 25 Right orchidectomy 11TI, Stage IIA 
and radiotherapy 
D. N. 52 Right orchidectomy MTI, Stage IVO L3 
and radiotherapy 
a Histology: 
MTU - Malignant teratoma undifferentiated. 
MTI - Malignant teratoma intermediate. 
MTT - Malignant teratoma trophoblastic. 
b For details See description of patients. 
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TABLE 4.1,. (contd) 
Name Age Previous Histolo ica a and clinical 
(years) treatment staging 
g 
of the tumour 
40 Left orchidectomy MTI, Stage IVO Ll 
and radiotherapy 
M. H. 23 Bilateral orchidectomy Right-MTI', Left -seminoma 
and radiotherapy Stage IVO L l' 
G. H. 32 Left orchidectomy MTI, Stage IVC L I' 
M. G. 19 Right orchidectomy MTI, ' Stage IIIB 
-,, -', A. D:, 23 Right orchidectomy ý'MTU, - Stage IVO L 2 and radiotherapy 
A. S. O. 22 Left orchidectomy MTU, Stage IVC L3 
I 
120 
is shown in Table 4.2. 
Overnight fasting blood (15ml) was-collected from each patient - 
and control subject by venepuncture. An aliquot (lml)'was transfe; red 
to a 5ml heparinised tube, mixed and stored at -40 
0 C. This was used' 
to measure the stimulation of transketolase activity by 'thiamine 
pyrophosphate.. Another portion (4ml) was transferred to a sequestrene 
tube, mixed gently and centrifuged. Aliquots (0.5ml) of the plasma 
were added to 2ml aliquots of 5% TCA. The solutions were mixed, 
centrifuged and the supernatant TCA extracts were used to determine 
plasma-ascorbic acid. The remainder of the blood was transferred to 
a heparinised tube, mixed gently-and centrifuged. The plasma was 
separated and aliquots were stored in sample tubes covered with foil 
0 
at T40 C. The residue of. red cells was washed with isotonic saline, 
centrifuged and the supernatant was discarded. The red cells were 
lysed by adding distilled water. The haemolysate was used to measure 
the stimulation of transaminase activity by pyridoxal 5-pho-sphate. 
e 
The haematocrit values of each blood sample was determined and 
used for the calculation of transketolase and transaminase activities. 
Statistical significance was calculated using either the students 
t-test, or the paired t-test in longitudinal studies. 
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Tabld 4.2.1. Response to therapy in patients treated on 
the Samuels regimen. 
0 
Name Response to 
therapy, 
G. T. W. Good response 
J. C. Static after 
Course I, 
progression later 
M. M. Fairly good 
response, lung 
metastases 
-regressed 
N. W. Good response, 
lung metastases 
regressed 
W. P. Good response, 
residual abdominal 
mass 
A'. G. Regression of 
tumour 
M. H. Partial response 
Other information 
Co 
* 
urse of radiotherapy later. 
Recurrence 2 months after completing 
chemotherapy 
Bulky lung metastases detected. 
Died later. 
Four more courses of chemotherapy and 
radiotherapy. Abdominal mass 
removed by*surgery. Patient well'. ' 
Patient well. 
Two more courses of chemotherapy and 
surgical removal-of residual tumour. 
Patient well. 
VB treatment poorly tolerated. 
Developed paralytic ileus after 
course I and course II given 2 
months later. 
Radiotherapy later and surgical 
removal of abdominal mass, but 
patient unwell. 
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Table 4.2.2. Response to therapy in patients treated on the 
Einhorn regimen. 
Name Response to other information 
therapy 
. A. S. No evidence of Pulmonary function affected as a active disease result of bleomycin treatment 
developed 'bleomycin lung's 
D. N. " Partial response Asymptomatic. " 
No change, Thoracotomy suggested. 
M. H. Good response Thoracotomy suggested. 
G. H. Marked regression Two further courses of chemotherapy. 
M. G. Regressing' 
A. S. O. - Dramatic. clearing Died of septicaemia and cardiac after course I arrest after course 3. Post mortem 
revealed persisting abnormal, ity 
in the lung. 
tcs C(tAe ýC) 6 (e-O rA Y Cz OLC 
CU M L&(Cxt on 
k 
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4.3 ANALYTICAL METHODS 
The plasma concgntrations of vitamins A and E, retinol-binding 
protein, prealbumin, - proteins, copper and zinc were determined by 
the methods described in Chapter Two. Other methods used for the 
first time are described below. 
Determination of plasma ascorbic acid. 
Total ascorbic acid in the plasma was determined by the method. 
of Denson and Bowers (1961). Total ascorbic acid, that is, ascorbic 
acid,, dehydroascorbic acid and diketogulonic acid was determined bý 
coupling with 2,4 dinitrophenyl hydrazine,, following oxidation of 
ascorbic acid. The resultant orange coloured compound was dissolved 
in sulphuric acid and the optical density was measured at 520nm using 
a Cecil spectrophotometer. The standard curve obtained is shown in 
Figure 4.1. 
e 
4.3.2. Determination of transketolase stimulation. 
The extent of stimulation of transketolase enzyme activity 
in vitro by thiamine py . rophosphate (TPP), the co-enzyme fOrm Of thiamine, 
was used as an index of the thiamine status of the individual 
(Dreyfus, 1962). A stimulation of greater than 15% is considered to 
be an indicator of thiamine deficiency. 
The transketolase activity in haemolyzed whole blood was 
determined by the micro-assay of Basu et al, (1974d). Transketolase 
catalyzes the following reaction: 
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Fig. 4.1. Standard curve for the determination of ascorbic acid 
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Xylulose 5-phosphate 
Ribose 5-phosphaf6 TPP, Mg r_-r I 
q. edoheptulose 7-phosphate 
Glyceraldehyde 3-phosphate 
An aliquot (50pl) of whole blood was incubated with 
ribose 5-phosphate (3.2mM) in the presence and absence of thiamine 
pyrophosphate (2mM). 
- 
The pH of the incubation mixture was maintained 
at 7.4. The reaction was stopped by adding 30% TCA, after incubation 
0 
for 30 min at 37 C. The amount of sedoheptulose was measured by the 
colour produced in the presence of cysteine and sulphuric acid. The 
optical density was measured at 510nm and 540nm using a SP-500 
spectrophotometer. The difference in optical density between 510 and 
540nm gives a measure of the sedoheptulose concentration. The standard 
curve obtained is shown in Fig. 4.2. Transketolase activity (Tk) was 
expressed as Pmoles of sedoheptulose formed/min/ml of haemolysate. 
TK TK 
% Stimulation by TPP 
with TPP 
x 100 
TK 
4.3.3. Determination of transaminase stimulation. 
It has been suggested that the in vitro stimulation of erythrocyte 
transaminase activity by pyridoxal 5-phosphate (B 6 PO 4) could be used as 
an index of vitamin B6 status in man (Sauberlich and Raica, -1964; 
Cinnamon and Beaton, 1970). The activities of both glutamate 
oxaloacetate transaminase (GOT) and glutamate pyruvate transa. minase 
(GPT) in the-erythrocytes were measUred in the presence and absence of 
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pyridoxal 5-phosphate. GOT catalyzes the following reaction. 
a-ketogl, utarate glutamate- 
GOT 
fj aspartate" B6 P04 o*aloacetate 
The GOT activity was measured by a modification. (Cheney et al., 
1965) of the method of Tonhazy et al. (1950). An aliquot (0.2ml) of 
the erythrocyte haemolysate was incubated with a-ketoglutarate and 
buffered aspartate (pH 7.4) at 370C for 10 min. The reaction was 
stopped by adding TCA. The oxaloacetate produced in the rea. ction was 
converted to pyruvate by adding aniline citrate. Pyruvate was 
converted to'"Jts phenyl hydrazone by treatment with 2,4,, dinitrophenyl 
hydrazine. The phenyl'hydrazone of pyruvate was extracted using 
water-saturated toluene. The colour produced by mixing an aliquot 
(I ml) of the toluene extract with 2.5% ethanolic potassium hydroxide 
was measured at 525nm using a Cecil spectrophotometer. 
In the determination of GPT Aich catalyses the reaction sh'own 
below, buffered alanine (pH 7.4) was used instead of buffered aspartate 
and 0.5ml of haemolysate was used. 
ct-ketoglutarate lutamate 
GPT 
aniline B6 P04 yruvate 
As pyruvate is produced by the reaction itself, the 
decarboxylation step using aniline citrate was omitted. The coloured 
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compound formed with 2,4 dinitrophenyl hydrazine was measured as 
described for GOT. The standard curves for GOT and GPT are shown 
in Figures 4.3 and 4.4 respectively. 
Transaminase activity Transaminase 
with B6 PO 4 acti vi ty % Stimulation =-x 100 
Transaminase activity 
The percentage stimulation of GOT in, the 8 control subjects ranged from 
0 65% and the stimulation of GPT ranged from 0- 30%. 
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4.4 RESULTS 
Pre-treatment values. 
_ 
The, pre-treatment pl4sma concentrations of vitamin. A, retinol- 
binding protein (RBP) and prealbumin in testicular teratoma patients 
were compared with those of a control group of healthy age-matched 
subjects. The plasma vitamin'A levels in teratoma patients were 
significantly (p < 0.01) lower (mean value = 50.2 
t 3.1 Vg/ml) th an 
that ofthe control group (mean value = 71.0 1 7.3 pg/100ml) (Fig. 4.5). 
Eight patients had vitamin A concentrations less than 45 pg/100ml, but 
these low' values did not correlate'with the staging of the disease or 
the presence of lung metastes. Six of these patients had malignant 
teratomas of the undifferentiated histological type. About fifty 
percent of the patients had Vitamin A concentrations within the normal 
range. The plasma RBP level was also significantly (p < 0.01) lower, 
with a mean value of 4.61 0.26 mg/100ml, as compared to the control 
group (mean va", ue = 5.97 0.31 mg/lOOm', ). Only 3 patients had*RBP 
. 
levels above the mean of the control group (Fig. 4.6). In addition, 
the plasma prealbumin concentrations of these patients were also 
significantly (p < 0.01) decreased (mean value = 20 ± 1.3 mgllOOml) 
as compared to the control group (mean value = 27 1.2 mg1lOOml)- 
Moreover, about a third of the patients had very low concentrations 
of prealbumin (Fig. 4.7). 
A highly significant correlation (p < 0.001 , -y = 0.73) was-, 
observed between vitamin A and RBP concentrations in the plasma of 
teratoma patientss but not in the controls (Fig. 4.8). Furthermore, 
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the plasma RBP levels were significantly (p < 0.02, y=0.52), 
correlated with the plasma prealbumin levels (Fig. 4.9). However, 
the correlation between vitamin A and prealbumin was not significant 
(Fig. 4.10). 
The concentration of vitamin E was similar in both teratoma 
patients and controls (Table 4.3). The plasma concentration of zinc 
was comparable in both groups, while that of copper was slightlys but 
not significantly elevated (Table 4.3). 
4.4.2. (a) Effect of chemotherapy (Samuels regimen). 
The changes in body weights and plasma total protein and albumin 
during chemotherapy in teratoma patients is shown in Table 4.4. The 
body weights decreased during each course of chemotherapy'and the 
effect was greatest during the second course. --The plasma total 
protein and albumin concentrations were not significantly altered. 
The plasma vitamin A concentration decreased after each course of 
chemotherapy and the change was significant in all courses except the 
first (Fjg. '4.11).. The concentration of vitamin A rose between the 
end of the first course of treatment and the beginning of the second. 
Furthermore, the plasma vitamin A levels showed a gradual stepwise - 
elevation during successive courses of chemotherapy. The vitamin A 
concentration at the beginning of the fourth course was significantly 
higher than the pre-treatment value. It is also of interest that 
the plasma vitamin A concentration remained elevated in a patient (N. W) 
who responded to therapy, A ile it showed no improvement in a-patient 
(J. C) whose tumour progressed (Fig. 4.12). 
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The concentration of RBP in the plasma also showed a similar 
stepwise variation (Fig. 4.13). A marked increase in the RBP level 
was observed at, the start of the-second course of chemotherapy. A 
decrease due, to chemotherapy occurred cafter each subsequent course.. 
The RBP concentration at the start of the fourth come was 
significantly (p, < 0.02) higher than the pre-treatment value. The 
plasma prealbumin concentration also showed a similar variation with 
time, but it was not significantly decreased by chemotherapy (Fig. 4.14). 
However, a marked elevation of prealbumin levels occurred at the start 
of the second course and it persisted during subsequent courstý of 
chemotherapy. It is also noteworthy, that the values at. the sta. rt 
of the fourth course were significantly (p < O.. Ol)higher than 
pre-treatment values. 
A highly significant decrease in plasma vitamin E-was observed 
at the end of the, first, two courses of chemotherapy (Fig. 4.15). 
However, in contrast to vitamin A, a significant improvempnt. in plasma 
vitamin E did not occur during successive courses of chemotherapy. 
The plasma vitamin C concentration did not change (Fig. 4.16) 
significantly during chemotherapy, although there was a slight gradual 
elevation during progressive treatment. The % TPP-effect was markedly 
increased after each course of, chemotherapy (Fig. 4.17). Similarly., 
the percentage stimulation of both GOT and GPT by pyridoxal 5-phosphAte 
were significantly elevated after each course of treatment (Fig. 4.18). 
The variation of zinc and copper concentrations in the plasma 
19. The plas"a z**nc levels du"ring''chemotherapy'is'shown in'Figure 4. m1 
decreased during treatment, but the fall was significant only in the 
first and third courses of chemotherapy. The mean value at the end of 
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the fourth course of treatment was almost identical to the . 
pre-treatment value. In contrast, the plasma copper levels were 
elevated after treatment. The rise in the concentration of copper 
was highly significant after the third and fourth courses. 
It is also noteworthy that the plasma, zinc levels were positively 
correlated with both vitamin A (Fig. 4.20) and RBP (Fig. 4.21) in the 
plasma. Moreover, a stronger correlation (-y = 0.49, p<0.01) was 
observed between zinc and RBP than with vitamin A. 
4.4.2 (b) Effect of chemotherapy (Einhorn regimen). 
The body weights of teratoma patients treated with the Einho'rn 
regimen were markedly decreased as a result of chemotherapy (Table 4.5). 
As with the Samuels regimen, chemotherapy did not change the values 
for plasma total, proteins-and albumin (Table 4.5). 
The variations of mean plasma vitamin A concentrations during 
(ýhemotherapy are shown in Figure 4.22. The cnncentration of vitamin A 
in the plasma in these patients was within the normal range, and thus 
differed in this respect from the patients treated with Samuels regimen. 
The levels 'decreased during chemotherapy and the fall was greater by. 
the sixteenth day of each course. However, the change by the 
sixteenth day was statistically significant only during the first and 
second courses. The magnitude of the fall did, in fact, decrease with 
successive treatments. 
The plasma RBP levels did not fall until after the seventh day 
during the first two'course-s. -- At I the sixteenth day, -the values were 
significan. tly lower than the pre-treatment value of the course, for 
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courses 1 and 4-(Fig. 4.23). The concentration at the start of the 
fourth course was significantly (p < 0.02) higher than the 
pre-treatment value. of the first course. The plasma prealbumin- 
concentrations were only slightly decreased during chemotherapy and 
showed a gradual elevation during successive courses of chemotherapy 
(Fig. 4.24)'.. As i. n the case of RBP, the plasma prealbumin level at 
the start of the fourth course of chemotherapy was significantly 
(p < 0.02)-higher than the values at the start of chemotherapy. 
The vitamin E concentration in the plasma fell significantly 
during the first three courses of chemotherapy with a rise between 
treatments (Fig. 4.25). The concentration of vitamin C in the plasma 
was not markedly altered by chemotherapy (Fig. 4.26). The percentage 
TPP effect increased during the first three courses of chemotherapy 
(Fig.. 4*. 27) and showed no evidence of returning to the pre-treatment 
value during the--list týjo, courses. The percentage stimulation of 
erythrocyte transaminases (GOT and GPT) by pyridoxal 5-phosphate also 
increased during chemotherapy (Fig. 4.28). A greater increase'in the 
stimulatory, effect was observed with GPT than with GOT. ' 
In contrast to Samuels regimen, the plasma zinc concentration of 
patients treated on the Einhorn regimen were not depressed, but slightly 
elevated (Fig. 4.29), and the increase was significant only during the 
fourth course.., The plasma copper concentrations were also signiýicantly 
elevated during the fourth course (Fig. 4.29). In contrast to the 
Samuels regimen-, the plasma zinc concentrations were not correlated 
with either, vitamin'A or RBP. 
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4.5. DISCUSSION 
The pre-treatmpnt concentrations of vitamin A and RBP were 
significantly'lower in patients with metastatic testicular teratoma 
than in, age-matched healthy male, subjects. This observation is 
similar to, that of patients with lung cancer (Chapter Two). 
Moreover, the observation of a correlation between vitamin A and 
RBP in teratoma patients, as in lung cancer patients, suggest that 
the low levels may be due to low levels of RBP, rather than a 
restricted dietary intake. There was considerable variation in the 
vitamin A concentration of teratoma patients, and the levels found in 
the five patients who did not have lung metastases were within,, the 
range. of those that did have lung metastases. Also, there was no 
apparent correlation between the vitamin A levels and the., staging of 
the tumour. However, it is of interest that six of the eight-patients 
WIZ had low vitamin A concentrations had malignant teratomas of the 
, ýndifferenltiated histological -type. Low viltaxin A level ,S were Pso 
observed in patients withundifferentiated lung cancer (see Chapter 
Two). This observation may be of great importance, in view of the, 
role of vitamin, A in controlling the differentiation of . ep, ithelial 
tissues. However, its significance is not clear at present. 
In contrast to patients with primary lung cancer, patients with 
metastatic. testicular teratoma had low prealbumin levels. Thus, 
the entire retinol-transport system was affected in the teratoma 
patientsland the subnormal vitamin A concentrations may have resulted 
fromImpairment of this system. This is further supported by the 
observation of, a correlation between RBP and prealbumin. 
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Low concentrations of vitamin A may occur in conditions. 
associated with impaired fat absorption. However, the observation 
of similar concentrations of vitamin E in both teratoma patients 
and in age-matched control subjects implies that the low concentrptions 
of vitamin A were not due to malabsorption of fat. Moreover, 
vitamin E is an important factor in the absorption anq biological 
utilisation of vitamin A (Bauernfeind et al., 1974; Jagadeesan and 
Reddy, 1978). Thus, as in the lung cancer patients, the low plasma 
vitamin A levels were not a result of impaired absorption or 
utilisation due to lack of vitamin E. 
It was suggested in Chapter Two that the low circulating levels 
of RBP could have been the result of a reduced availability of zinc. 
However, in patients with metastatic testicular teratoma, the plasma - 
levels of both zinc and copper were similar to the controls. It thus 
seems possible th at in these patients the low prealbumin and RBP 
may be a reflection of-decreased hepatic synthesis due to liver damage 
by the tumour. 
Treatment of these patients with *either the Samuels or Einhorn 
regimens caused a marked fall in body weights. Samuels and co-workers 
(1976) have reported a median weight loss of 4.95 kg per course in 
patients with testicular tumours treated with their regimen, while 
adjunctive intravenous hyperalimentation. resulted in a mean weight'pin 
0.45 kg per course. In a recent review, Donaldson-and Lenon (1979) 
have reported a mean weight loss of 2.9% of the body weight in 12 men 
with stage III non-seminomatous testicular carcinoma treated with the 
Einhorn regimen. In other studies (Copeland et al., 1975) the actual 
response to chemotherapy in patients with advanced cancer at various 
sites, suc h as the lung, colon and testis, was improved by intravenous 
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hyperalimentation. These workers also observed a positive 
correlation-between the-nutritional status and the response to ., 
therapy in patients with non-oat cell carcinoma of the lung. 
Although there is itill some controversy as to whether nutritional 
supplementation ofcancer, patients feeds the patient or the tumour, 
evidence is'accruing, that in-a, number of circumstance§, nutritional 
support isýbeneficial (Calmon,, 1979) and there is no real evidence 
to. the contrary in humans. -Intravenous hyperalimentation though 
beneficial,, introduces. the patient to the risk of infection, 
particularly because of the impaired immunocompetence, 'often found in 
cancer patients. Therefore, enteral nutrition.. may-have a greater 
beneficial&effect., 
The-patients with testicular-teratoma showed other metabolic 
abnormalitiesAuring chemotherapy. Thus, the plasma-vitamin A----I-* 
concentration-fell on treatment with both chemotherapeutic regimens. 
Howevers there was a rise, in theiplasma, vitamin A concentration. to - 
higher than pre-treatment values-at: the start of subsequ6nt courses of 
chemotherapy in patients treated with the Samuels regimen, but not with 
the Einhorn regimen. This difference may be due to the fact that 
the, patients given the Einhorn regimen, had mean pre-treatment vitamin A 
levels within the normal range. T he fall in vitamin A concentration 
was markedly reduced during the third and fourth courses of 
chemotherapy in patients treated with, the Einhorn regimen. The 
elevation of vitamin A may seem to be of some prognostic significance, 
because, the-levels remained, elevated in a patient-who responded to 
chemotherapy with the Samuels regimen,, whereas,, the levels, -fell. in a. 
patient whose, tumour was progressing. Such, a comparison was not 
possible with the Einhorn regimen, as most of the patients responded 
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to treatment and no patient had tumour progression during treatment. 
The results of the two patients are in agreement', with the finding 
by Soukop and Calmon (1978) of a poor respopse to chemotherapy'which 
was associated witý a, low level of vitamin A.. 
The plasma RBP concentration in patients treated, w. ith the 
Samuels regimen, folloVed a pattern similar to vitamin-A, with a 
dramatic rise between the end of the first course and the start of 
the secon, d course of chemotherapy. This rise was maiptained at thel- 
start of, subsequent courses with a fall during chemotherapy. , 
In- 
contrast,,, in patients treated with the Einhorn regimen,, the pl. asma, RBP 
levels rose initially and decreased to lower than pre-treatment values 
on the sixteenth day, in,, the. first two courses of therapy.. The increase 
. in, RBP was observed after the period of treatment-with cis-DDP.,. The 
kidney. is the major organ involved in the catabolism of RBP,, "and 
elevated plasma RBP levels have been reported in-patients with impaired 
renal, function (Peterson, l97-lý.,,, Cis-DDP is notably toxic io the 
kidney, (Tally, et al., 1978), and. the transient rise in RBP may reflect 
its decreased c5tabolism as a result of disturbt. nces of kidney,, function. 
The plasma RBP levels were elevated to higher than pre-treatment values 
of the first course at the start of subsequent'courses of chemotherapy 
in both chemotherapeutic regimens. The plasma prealbumin 
concentration also. followed a similar trend in both chemotherapeutic 
regimens rising to higher than pre-treatment values at the start of 
second and subsequent courses of chemotherapy. 
Both RBP and prealbumin are synthesized in the liver (Smith and 
Goodman, 1971). It is possible that. the, presence-ofthe, tumour exerted 
a distant effect on, the liver-which was removed by chemotherapy. It 
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is noteworthy that only ond patient whose vitamin profile was 
followed during chemotherapy had evidence of metastases in the 
tr% pj3Pckrd ptta%tA rA 
liver. Thus, it seems unlikely that tht; dýnjeýwas due to 
dissemination of the tumour to the liver in other patients. 
As early as 1957, Begg speculated that the presence of a tumour 
may cause metabolic disturbances in distant organs. Such metabolic 
abnormalities are now well documented (Theologides, 1972; Hall, ' 1974; 
Costa, 1977; Theologides, 1979). Cancers frequently produce peptideýs 
and other small molecules probably as a result of derepression of 
various genomes (Stonehill and Bendich, 1970; Hall, '-1974; Islam, 1978).. 
The hypothesis has been advanced that novel and common peptides and 
other small moleculesfrequently produced by the tumour may modify 
the activity of host enzymes'through all6steric or other e. ffects, 
activating and inactivating various enzymes in the tumour-free tissues 
of the host (Theologides, 1972; Theologides, 1974). These 
alterations in activities of host enzymes result in changes in various, 
biochemical reactions and may throw the metabolism of the host into a 
chaotic state. However, conclusive evidence to support this hypothesis 
is still lacking. ' 
When tumour growth is controlled by chemotherapy, the effects on 
some distant organs, such as the liver, in teratoma patients, may be 
removed and the normal synthesis of RBP and prealbumin could be- 
restored. This would in turn increase the amount of vitamin A in 
ci rcul ati on. 
Chemotherapy also caused a fall in the concentrations of 
vitamin E and a decrease in status with respect to water-soluble 
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vitamins, thiamine and pyridoxine. These decreases may be due 
to reduced food intake and damage to the gastrorintestinal týact 
which are side effects common to all three antineoplastic agents 
(Ohnuma and Holland, 1977). With the Samuels regimen the values. 
tended to return to pre-treatment values during the interval between 
courses. In contrast, in the Einhorn regimen, the percentage TPP 
effect showed no tendency to return to pre-treatment values in the 
ast two courses. us, t iamine eficiency was aggravate y 
progressive treatment. In marked contrast to vitamin A, which is 
stored in the liver, the B vitamins, thiamine and pyridoxine are not 
stored in the body to any appreciable extent and are therefore 
dependent on normal dietary intake and absorption. 
A fall in the concentration of plasma zinc was observed in 
patients treated with the Samuels regimen, but not the Einhorn regimen. 
Furthermore, the plasma zinc levels were positively correlated with 
both vitamin A and RBP in patients treated with the Samuels regimen. 
Thus, decreased zinc may be a contributory factor in affecting the 
synthesis or release of RBP durirg treatment with this regimen. ' The 
plasma zinc levels of patients treated with the Einhorp regimen, 
however, were not lowered by chemotherapy but in fact slightly 
elevated. This difference could be due to an alteration in the trace 
element balance by administration of large doses of a heavy metal 
complex, namely cis-DDP. Moreover, in contrast to Samuels regimen 
there was no correlation between. zinc and RBP. 
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CHAPTER FIVE 
EFFECT OF, BLEOMYCI-N AND VINBLASTINE ON 
, 
NORMAL HEALTHY MALE RATS 
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5.1 -INTRODUCTION 
The antineoplastic agents, bleomycin and vinblastine, are 
widely used in the treatment of cancer and constitute the Samuels 
regimen for the treatment of metastatic testicular teratoma. The 
use of these drugs, however, has been frequently found to be 
associated-with a number of side effects, including anorexia, nausea 
and vomiting and mucosal ulceration (Donaldson, 1977), which may in 
turn precipitate a number of nutritional*-problems. - 
,1 Patients with lung cancer and metastatic testicular teratoma 
had low plasma levels of vitamin A and of its carrier protein, retinol- 
binding protein, -RBP (see chapters 2-and 4). Moreover, the low RB P 
levels were associated with low plasma zinc levels, in, lung cancer 
patients and, with low prealbumin levels, in teratoma'patients. - 
It was shown that the abroripalities in vitamin A metabolism'in 
teratoma patients were exacerbated. by treatment with cytotoxic drugs, 
such as vinblastine and bleomycin (see chapter 4). It is therefore 
of paramount importance to elucidate whether these drugs affect 
vitamin A metabolism in healthy animals. The present study was 
undertaken to investigate the effect of vinblastine and bleomycin, 
administered either singly, or in combination (in doses comparable 
IC to that of humans), on the plasma and tissues ol normal healthy animals. 
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5.2 EXPERIMENTAL PROTOCOL 
Normal healthy male Wistar-Albino rats weighing approximately 
200g. were used in''all experiments. ' 'They were kept in"individual 
cages and fed stock.. pellet food-(Spiller) and water'as described 
below. 
5.2.1 Iffect of bleomycin 
Fifteen rats matched according to body weight were divided 
into, three groups, each of five anim, als. 
I 
GroOp I was given O. Iml 
of, 0.9% saline subcutaneously, and served as controls. Group. 2. 
was given O. lml of bleomycin (Lundbeck Limited) in saline (3mg/kg 
bodyýweight, twice daily, subcutaneously) a. nd, food and water,, 
ad. libitum. , 
Group 3 (pair-fed control) was given the same amount 
of food, consumed by the bleomycin-treated animals and water ad libitum. 
All animals were treated for five successive days, their body weights 
and food and water intakes were measured daily. The animals were 
killed on the sixth, day. Blood was collected by cardiac puncture 
into hs; ýpa-. -inisq-, J tuýes and, the plasma, separated. The li'Vers we're 
removed and wei, ghed, and, the, plasma and livers were stored'at -4.0 
0C 
until analysed, 
5.2.2 
_Effect 
of 
-vinblastine, 
Fifteen rats, matched according to body weight were'divided- 
into three groups. each of five animals. Group I was'given O. Iml" 
of 0.9Z saline in'traperitoneally o'nc'e daily, and food and water 
ad libitum. These animals served as controls. The animals in 
group 2 were given O. Iml of vinblastine (Lilly Laboratories) in 
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0.9% saline (0.25mg/kg body weight, intraperitoneally, once daily) 
and food and water ad libitum. The animals in, group 3 were ýair- 
fed with the vinblastine group. All animals were weighed daily 
and the food and water intakes were measured. The animals were 
treated for two successive days and killed on the third day; they' 
were bled and their livers removed as described earlier (5.2.1). 
5.2.3 Effect of vinblastine in combination with bleomycin 
In this study, vinblastine was administered in combination 
with bleomycin'in a similar modality to that used in clinical 
pra ctice. 
Fifteen rais', matched according to body weight were divi . ded 
into three groups, each of five animals. The animals in group 1 
(vinblastine-bleomycin group) were treated with vinblastine in 0.9% 
saline (0.25mg/kg, body weight, intraperitoneally, once. daily) on 
days I and 2, and bleomyc. in in saline (3mg/kg body weight, 
subcutaneously, twice daily) on days I to 5 inclusive. Group 2 
was given food ad libitum and used as 'ad libitum controls', while 
group 3 was given the same amount of. food consumed by the vinblastine- 
bleomycin group and used as pair-fed controls. I 
All three groups 
were given water ad libitum. The animals were treated for four such 
courses. with a two-day intervalbetween courses., Their body, weights 
and food intakes were measured daily. The animals were killed on-,, 
the eighth day, after starting the fourth course of treatment; blood 
and livers were taken as described earlier (5.2.1). 
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5.2.4 Effect of vitamin A supplements on vinblastine treatment 
Twenty four rats were divided into three groups, each of eight 
animals. Group I (vinblastine and. vi'tamin A group)-was given 
retinol (vitamin A)-in corn oil (3000 I. U. per animal, intraperitoneally) 
and vinblastine in ýaline (0.25mg/kg body weight, intraperitonealiy) 
three hours later. Group 2 (vinblastino group) was given the same. 
volume of corn oil intraperitoneally, and vinblastine (0.25mg/kg body 
weight) three hours later. Group 3 was given the same amount of 
vehicle (corn oil and saline) and served as controls. All animals 
were given food and water ad libitum and the body weights and food and 
water intakes were measured daily. The animals were treated for two 
successive days and killed on the third day; their blood and livers 
were taken as described earlier (5.2.1). 
5.2.5 Effect of vitamin A and zinc sulphate supplementation on 
vinblastine treatment 
Thirty two rats were divided into four groups, each of eight 
animals. Group I (vinblastine, vitamin A and zinc sulpha, te group) 
was given retinol in corn oil (3000 I. U. per animal, intraperitoneally) 
and zinc sulphate in 0.9% saline (5mg/kg body weight, intraperitoneally) 
and given vinblastine in 0.9% saline (0.25mg/kg* body weight, 
intraperitoneally) three hours later. Group 2 (vinblastine and 
vitamin A group) was given retinol in corn oil and vinblastine in 
saline three hours later. Group 3 (vinblastine group) was given the 
same volume of corn oil, and vinblastine three hours later. Group 4 
was given the same volume of vehicle (corn oil and saline) and served 
as controls. All animals were given food and water ad libitum. 
Their body weights and food and water intakes were. measured daily. 
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The animals were treated for two successive days and killed on the 
third day; 
- 
their blood and livers were taken as described earlier 
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5.3 ANALYTICAL METHODS 
The concentrations of vitamins A and E, zinc and proteins 
in the plasma were determined by the methods described in chapter* 
two. The vitamin A in the liver was determined by the fluorometrid 
method described in. chapter three and the zinc content of the liver 
was determined by the method described below. 
5.3. Determination of zinc in the liver 
About 0.5g of-liver homogenate was weighed accurately into each 
acid-washed conical flask and 5ml of concentrated nitric acid,, (A. R) 
and lml of perchloric acid (A. R) was added. The flasks were 
allowed to stand for 15 minutes and heated gently until'the liver 
had completely dissolved. The temperature was gradually increased 
to 2000C and finally to 2500C when the solution became colourless. 
This'temperature was maintained until the solution had completely 
evaporated to dryness. The resulting residue was redissolved in 
10ml of 1% nitric acid with warming. Standard zinc solutions were 
prepared in 1% nitric acid. The zinc content was measured by atomic 
absorption spectroscopy as described for plasma zinc (chapter two). 
The standard curve obtained is shown in figure 5.1. 
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Fig. 5.1. Standard curve for the determination of tissue zinc. 
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5.4 RESULTS 
5.4.1 Effect of bleomycin 
Treatment of normal male rats with bleomycin (6mg/kg body 
weight/day) for five successive days resulted in a marked 
reduction in food intake (Table 5.1). The body weight gain 
of the bleomycin-ireated animals was not only lower than that 
of the ad libitum controls, but also than that of the pair-fed 
controls. It appeared, -therefore, that the reduced food in take 
as a consequence of bleomycin therapy accounts only in part for. 
the restricted growth rate. Food restriction caused a decrease in 
liver weight relative to body weight in the pair-fed controls. 
Treatment with bleomycin did not have any effect on the absolute 
liver weight or liver weight relative to body weight When compared 
with ad libitum controls, but was slightly higher than in the 
pair-fed controls (Table 5.1). 
The concentration of vitamin A in the plasma of the animals 
given bleomycin was lower than that of either the ad libitum, (p < 0.001) 
or pair-fed (p < 0.05) controls (Table 5.2). The mean plasma vitamin A 
levels of the pair-fed controls were significantly lower than that 
of the ad libitum controls. The plasma vitamin E levels were 
significantly lower in both bleomycin-treated and pair-fed'controls 
than in the ad libitum control group (Table 5.2). The vitamin A 
content of the liver showed a similar pattern to that of the plasma 
with the amount in the bleomycin-treated animals being significantly 
lower than that of either of the controls (Table 5.2). 
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The plasma zinc concentration was not affected significantly 
by treatment with bleomycin, while the total amount of zinc was 
lower in the livers of both bleomycin-treated and pair-fed 
animals when compared with ad libitum controls (Table 5.2). 
The plasma total pýoteins and albumin were similar in the three 
groups (Table 5.2). 
5.4.2 Effect of vinblastine 
Giving vinblastine for two successive days caused. a highly 
significant (p < 0.001) loss in body weight as compared to both 
pair-fed and ad libitum controls. (Table 3). The gain in body 
weight in the pair-fed group was restricted to a mean value of 
1.2g, but there was considerable difference between individual rats-- 
as is shown by the large standard error of the mean. Furthermore, 
the food intake of vinblastine-treated animals was significantly 
(p < 0.001) lower than that of ad libitum controls (Table 5.3). 
The liver of the vinblastine-treated rats weighed significantly, 
less than that of either of the control groups both in absolute 
terms and relative to body weight (Table 5.3). 
The plasma vitamin A concentration in the vinblastine-treated 
animals was significantly lower than that of either of the two 
control groups (Table 5.4). In contrast to the effect of bleomycin 
the plasma vitamin E levels were not significantly altered by 
vinblastine treatment. As with bleomycin, there was a decrease in 
the hepatic vitamin A content in parallel with the changes in plasma 
level (Table 5.4). The plasma zinc level, however, was slightly 
lower in both bleomycin-treated and pair-fed groups than in the 
ad libitum controls, while the total zinc content of the liver was 
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significantly decreased only in the vinblastine-treated animals 
(Table 5-4). 
The plasma total protein and albumin concentrations were 
significantly decreased by vinblastine treatment and this effecf 
is independent of food intake (Table 5-4). 
5.4.3 Effect of vinblastine in combination with bleog! ycin 
The body and liver weights of rats treated with four courses 
of a combination of vipblastine and bleomycin are shown in Table 5.5. 
The body weight gain over the period of four courses of treatment was 
si. gnifiqantly lower in animals treated with vinblastine and 
bleomycin when compared with both pair-fed and ad libitum controls. 
Thus, during each course of treatment the restriction in body weight 
gain tended to be greater on days one to three (that is, during and 
immediately after. treatment with vinblastine) (Fig. 5.2). 
Furthermore, the effect of each successive course on the overall 
vinight gain appeared to increase. The gain in body weight wivs*also 
restricted in the pair-fed animals, but to a lesser extent. The 
decrease in body weight during days one to three of each course was 
accompanied by a fall in food intake on those days (Fig. 5.3). The 
absolute liver weights were lower in both treated animals and 
pair-fed controls, than in the ad libitum controls, while the liver 
weight relative to body weight was lower only in pair-fed controls 
(Table 5.5). 
The concentration of vitamin A in the plasma and the total 
amount in the liver were markedly reduced following treatment with 
vinblastine and bleomycin when compared with. the values in the two 
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control groups (Table 5.6). The pair-fed group had a mean 
hepatic vitamin A value which was intermediate between treated 
animals and ad libitum controls. Agaip, in contrast to vitamin A, 
the plasma vitamin E concentration was similar in the three groups 
(Table 5.6). Thq concentration of zinc in the plasma and the 
amount of zinc in. the liver, was lower in the treated group than 
ad libitum controls, but not significantly lower than those that 
were pair-fed (Table 5.6). 
The concentrations of plasma total proteins and albumin were 
significantly (p < 0.01) lower in the treated animals than i. n the 
pair-fed of ad libitum controls (Table 5.6). 
5.4.4 Effect of vitamin A supplementation on vinblastine treatment 
Table 5.7 shows that treatment with vinblastine for two 
successive days resulted in loss of body weight and that pretreatment 
of the animals with retinol (Vitamin A) counteracted the detrimental 
"fect to some exten' vir. bliAstine 1hus, the animals treated with_ 
alone lost a mean weight of 6.6g, while the animals treated with 
vitamin A before administration of vinblastine had a mean body weight 
gain of 1.3g. As previously demonstrated, the loss of body weight 
in the vinblastine-treated animals was partly due to the anorectic 
effect of the drug. Pretreatment with. vitamin A significantly 
reduced the anorectic effect, but did not restore the food intake to 
that of the controls (Table 5.7). Pretreatment with vitamin A did, 
however, prevent the significant loss of liver weight induced by the 
drug. 
The administration of vitamin A with vinblastine partially 
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prevented the fall in plasma vitamin A concentration caused. by the 
drug when given alone (Table 5-8). Giving 'Vitamin'A not only 
prevented the fall in hepatic vitamin A produced by the drug, but 
raised the level to higher than that found in the controls (Table . 5.8). 
The plasma vitamin E and zinc-concentrations and the zinc content 
of the liver were similar in the three groups (Table 5'. 8). 
The decrease in the plasma total protein and albumin concentration 
was prevented by treatment of the animals with vitamin A before 
vinblastine administration (Table 5.8). 
5.4.5 Effect of vitamin A. and zinc sulphate supelementation on 
vinblastine treatment 
A- 
Giving zinc sulphate in addition to vitamin A before administration 
of vinblastine did*not enhance the beneficial effect of vitamin A 
in reducing the loss in body and liver weights and increasing the food 
intake (Table 5.9). 
I 
Furthermore, there was no impr . ovement in the plasma and hepatic 
vitamin A status of rats pretreated with zinc sulphate and vitamin A 
over those caused by pretreatment with vitamin. A alone (Table 5.10). 
However, the plasma zinc level was significantly (p, < 0.01) raised in 
zinc sulphate and vitamin A pretreated animals compared with the other 
three groups (Tabl e 5.10). The hepatic zinc content was only 
slightly increased in the former group.. The plas ma protein levels 
of the vitamin A and zinc sulphate pretreated rats were similar to 
those pretreated with vitamin A alone (Table 5.10). 
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5.5 DISCUSSION 
0 
In agreement with the observations on cancer patients (Ohnuma. 
and Holland, 1977), the administration of. both bleomycin and,, 
vinblastine to normal healthy male rats caused-anorexia, with-a 
consequent decrease in body weight gain. In fact, vinblastine 
though given for only two days caused a substantial decrease, in 
body weight with a greater decrease in food consumption., Moreover, 
when animals were treated with a combination of the two drugs in 
a, regimen comparable to that administered to human patients with 
metastatic testicular teratoma, a greater decrease in food. intake 
and body weight gain was observed during and after vinblastine 
administration. The body weight gained by the rats decreased 
considerably during the third and fourth course so that the curve 
for the body weight diverged considerably from that of the. pair-fed 
controls. Thus the effect of the drugs on body weight gain was 
not entirely accounted for by the anorectic effect of. these drugs. 
It was clear that, there was an additional toxic effect on tho body 
tissues. 
The only organ. that was weighed in these studies was -the liver. 
The decrease in liver weight caused by bleomycin was entirely 
accounted for by the decreased food intake although there was a 
suggestion that the liver was affected rather less than the remainder 
of the body. Vinblastine, on the other hand, caused a. fall in liver 
weight which was greater. than expected, for the reduced foodAntake. 
The effect on the liver was relatively rather greater, than that on the 
remainder of the body., Hence there was a small fall in the 
percentagq contribution of theliver to the body weight. When 
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bleomycin and vinblastine were given together the effect of 
vinblastine on, the liver-appeared to be counterbalanced by bleomycin. 
-Both bleomycin- and vinblastine, when given independently or 
combined in courses caused a fall in'plasma and liver vitamin A. 
Thus both drugs caused a mobilisation of vitamin A from the liver- 
to, help to maintai*n the plasma concentration. In view of the 
fact that the vitamin A concentration fell in-the plasma as'well as 
in the liver, it. spems unlikely, that the decrease in plasma vitamin A 
was simply due to impaired mobilisation. It is also possible that 
the trauma caused by treatment with these cytotoxic agents increased 
the requirementfor vitam. in A. , In fact, -Levenson et al. 
(1972), have 
shown, that the. requirement for the vitamin is increased by wounding 
and other forms of trauma. 
The plasma total protein and albumin concentrations were not 
affected by bleomycin treatment, while a significant decrease 
occurred due to vinblastine administered either alone, or in 
combination with bleomycin. It-is to be noted -that the effect of 
vinblastine on the general body. tissues was considerable. 
Thus, the toxic manifestations of these two antineoplastic 
agents occur not only in patients with neoplastic disease, but also 
in healthy experimental animals. 
In a study to determine whether some of these effects could be 
alleviated by vitamin A, the animals were treated with retinol 
(vitamin A) three hours prior to administration of vinblastine. The 
loss in body weight was drastically curtailed in the vitamin A 
pretreated animals and, in fact, a slight body weight 'gain was 
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observed. Moreover, the food intake was also increased in Animals 
pretreated with vitamin A. Furthermore, the decrease in liver 
weight was prevented by treatment of the animals with vitamin A. 
p 
It thus appears that giving vitamin A reduces some of the 
detrimental effects of vinblastine on body weight, liv6r weight and 
food intake. Moreover, the fall in plasma proteins on treatment 
with vinblastine was also prevented by pretreatment with vitamin A. 
Pretreatment of rats with zinc sulphate in addition'to vitamin A 
did not enhance the beneficial effects of the latter. 
Several studies have shown that vitamin A enhances the action of 
some antitumour agents such as cyclophosphamide (Anton and Brandes, 
1968) and 1,3 bis (2-chloroethyl) 1-nitroso urea - BCNU (Cohen and 
Carbone, 1972) in mice. Furthermore, vitamin A accelerates the 
regression of a skin tumour, keratoa. canthoma, by 5-fluorouracil in 
rabbits (Prutkin, 1973). 
The present study indicates that vitamin A alleviates some of 
the adverse effects of the antineoplastic'agent, vinblastine. And, 
it is tempting to suggest that vitamin A may have the same beneficial 
effects in patients treated with vinblastine, either singly or in 
combination. 
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CHAPTER SIX 
GENERAL DISCUSSION 
0 
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It is now well-known that vitamin A plays an important role in 
growth, reproduction, visual function and the differentiation of 
epithelial tissues. It is also involved in the maintenance of 
mesenchymal structures, such as cartilage and bone (Moore, 1967).. 
There have been a number of reports based largely on the results of 
studies in experimental animals which suggest that vitamin A 
deficiency is related to the genesis of cancer of epithelial tissues, 
such as those of the respiratory and genitourinary tracts 
(Sporn et al., 1976). Biochemical findings in a number of studies 
also suggest an association between low plasma vitamin A levels and 
cancer of some epithelial tissues in man. For example, vitamin A 
deficiency has been reported in patients with cancer of the stomach 
(Abels et al., 1941) and cervix (Wynder, 1969). However, the low 
plasma v, itamin A levelslobserved in patients with cancer of the 
stomach may be largely due. to a prolonged poor dietary intake and 
absorption iP the presence of the slow growing tumour. * Recently, 
Ibrahim-et al. (1977) observed low plasma levels of vitamin A in 124 
males and 79 females with squamous cell carcinoma of the, oral cavity. 
and oropharynx when compared to. controls matched for'age'and sex. 
In the present study, subnormal circulating vitamin A levels 
were observed in both groups of1patients studied, namely patients 
with lung. cancer and those with advanced testicular teratoma, many 
of whom had met, astases in the lung. The lung cancer patients had 
serum vitamin A concentrations lower than patients having non-malignant 
lung diseases, or other non-malignant diseases. 'The plasma 
vitamin A levels of patients with metastatic testicular teratoma 
were lower than those of healthy age-matched male subjects. The' 
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studies on lung cancer patients confirm tI he earl I ier work of Basu 
and co-workers (1976), who found the plasma vitamin A levels of 
lung cancer patients to be significa I ntly lower than I those of 
patients having non-malignant lung diseases or age-matched healthy 
subjects. The low circulating vitamin A levels may have been 
caused in a number of ways, some of which have been examined in 
this study. 
Restricted dietary intake 
There, is epidemiological evidence pointing to an'as§ociation 
between low dietary intake of vitamin A and the incidence of lung 
cancer. Bielke (1975) in a retrospective study of 8278 residents 
in Norway found that low dietary vitamin A intake was negatively 
associated with lung cancer at all levels of smoking. However, as 
pointed out earlier (p. 20) the results of this study must be viewed 
with caution as it did not take into consideration the ingestion of 
synthetic vitamin preparations or, vitamin A-rich animal foods, such 
as liver. In another study, Mettlin and co-workers (1979,1 nbserved 
that high dietary intake of vitamin A reduces the relative risk of 
development of lung cancer, particularly in heavy smokers. These 
studies,, are suggestiveof a role for the vitamin in the aetiology of 
lung cancer. There are obvious difficulties in establishing such 
a relationship, and what appears to be necessary iý a long term 
combined epidemiological and biochemical study of a population 
'at risk' extending over several decades. 
Impaired absorption 
Vitamin A or its precursor is absorbed. into the intestinal 
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mucosal cells along with the products of digestion of dietary fat 
and re-esterified within the intestinal mucosa. The retinyl 
esters so formed are circulated as constituents of chylomicrons. 
-Thus, 
low plasma levels of-vitamin A might result from the 
malabsorption of fat. However, the finding of-normal levels of* 
vitamin E, another fat soluble vitamin in both groups of patients brIAS ýO 
exclude. this possibility. 
Protein deficiency 
Depressed plasma vitamin A levels have been observed in 
conditions associated with protein deficiency. For example, *in a 
group of Egyptian children with protein-energy malnutrition, low 
serum concentrations of vitamin A, RBP and prealbumin were observed., 
along with low concentrations of albumin and total protein (Smith 
et al., 1973b). Supplementation with calories and protein without 
concomitant vitamin A therapy was found to cause a gradual elevation 
of vitamin A, RBP and prealbumin to normal levels. Further, -, I 
evidence for the requirement of dietary protein as a, source of amino 
acids from which RBP can be synthesized for normal retinol transport 
to be established, has been reported in studies on a group of- . 
malnourished children in India (Venkataswamy et al., 1977). * Low 
plasma protein levels may occur in cancer patients either due to, 
decreased synthesis (Steinfeld, 1960; Mariani et al., 1976), or to 
loss from the intestine (WaTdmann et al. j 1977). However, the 
plasma total-protein and albumin levels were within the normal range 
in the two groups of patients studied. -, These observations suggest 
that the low vitamin A levels observed in lung cancer patients and 
those with metastatic testicular teratoma were not a manifestation 
of generalised nutritional deficiency, but rather a specific effect 
on vitamin A metabolism. 
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mpaired mobilisation 
In contrast to plasma proteins, the circulating RBP levels 
were significantly lower in patients with lung cancer, as well a§ 
in those with metastatic testicular teratoma. Moreover, the 
plasma RBP levels showed a strong positive correlatio. n*with plasma 
vitamin A levels in both groups of patients. Thus, it is possible 
that the low vitamin A levels arose as a result of low 
concentrations of RBP. Or alternatively, low vitamin A levels 
might prevent the secretion of RBP from the liver, as has been noted 
in vitamin A-deficient experimental animals (Muto et al., 1972). 
The block in RBP secretion seen after vitamin A depletion is highly 
specific for. RBP. Thus, neither vitamin A depletion and deficiency, 
nor retinol repletion of deficient rats significantly altered plasma 
levels of prealbumin (Navab et al., 1977). 
The patients with metastatic testicular teratoma. differed from 
the lung cancer patients, however, in having low plasma prealbumin 
levels in addition to low RBP levels. Thus, the low concentrations 
of plasma vitamin A and RBP in the teratoma patients could not have 
been due to dietary vitamin 'A deficiency, but may *reflect impaired 
mobilisation as a result of decreased hepatic synthesis of RBP and 
prealbumin. 
Very little is known about the mechanism of secretion of RBP 
from, the liver. . Figure 6.1 summarises the information available 
on the metabolism of vitamin A and RBP in the liver cell. 
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Amino 
Acids 
Hydrolysis 
Retinol 
Hydrolysis' 
2 10 
Holo-RBP yro; 
Fig. 6'. 1. - Diagram summarizing the. metabolism of vitamin A ýand 
RBP i n. the 1 iver cel I (f rom Smi th and Goodman, 
. 
1979)_. 
RBP synthesized in the microsomal fraction of the liver associates 
wi th retinol released from the hydrolysis of retinyl, esters and is 
secreted into the circulation via the Golgi apparatus (Glover et al, 1974; 
Smith and Goodman, 1979). The secretion of RBP and prealbumin 
appear to betwo independent processes with the formation of 
RBP-prealbumin complex occuring in the plasma (Smith and Goodman, 1979). 
These_workers suggest that molecular signals from. peripheral tissues - 
may depress or stimulate the synthesis and secretion of RBP, and hence 
vitamin A, from the liver. However, the nature. of these signals has 
not yet been elucidated. 
It is of interest that, in the patients with testicular teratoma, 
the release of vitamin A, -RBP and prealbumin from the liver seemed 
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to be impaired, although these patients (except for two) h ad no 
evidence of spread of the malignant disease to the liver. Thus, 
it seems possible that the synthesis and possibly the secretion 
of RBP may be impaired by damage to the liver, by a distant effect 
in the presence of the tumour elsewhere. Theologides (1979) 
speculated that tumours synthesize novel and common polypeptides, 
or other molecules which are released into the circulation and cause 
profound metabolic-alterations in the function of tumour-free organs 
of the host. Rapp (1973) and Calman and McAllister (1975) explained 
the lower coenzyme A levels in the livers of tumour-bearing animals 
when compared to their normal counterparts by suggesting that these 
differences may be dueto metabolic abnormalities occurring in the 
non--involved organs ofthe tumour-bearing host. 
In contrast to the situation in patients with testicular teratomal 
lung cancer patients had. serum prealbumin levels comparable to those 
of controls. However, lung cancer patients had subnormal serum zinc 
levels, which were related to low vitamin A and RBP levels. Other' 
workers. have also reported low circulating zinc levels in patients 
with lung cancer (Davies et al., 1968; Davies, '1972; Andrews, 1979). 
Thus, the low vitamin A levels seem to be in some way related to 
the deficiency of zinc. 
A'relationship between zinc*and vitamin A metabolism has been 
demo nstrated in studies on experimental animals (Smith et al., 1974; 
Duncan and Hurley', 1978; Ette et al.,, 1979). - An association 
between zinc deficiency'and vitamin A metabolism, has been reported 
in patients with alcoholic cirrhosis (Morrison et al., 1978), in- 
healthy adolescents (Michaelsson et"al., 1976)., and in male subjects 
. 11 , with severe acne (Michaelsson et al., 1977). A study on zinc7 
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deficient rats suggest that the low plasma vitamin-A levels seen 
in zinc deficiency can be attributed to an impaired ability of 
the zinc-deficient rat to mobilise vitamin'A from the liver as 
the RBP complex (Smith et al., 1974). These workers suggest that 
zinc-deficiency interferes with the synthesis of RBP by the liver. 
It is also possible that zinc exerts its effect on vitamin A 
metabolism at other sites. Smith and Goodman (1979)'speculate on 
the pos'sibility that microsomal'RBP may repr - esent an intra-hepatic 
precursor - pro RBP, which is converted to RBP'during the process 
of secretion. In view of the fact that zinc is a co-factor for 
proteolytic enzymes such as'carboxyPeptidases in man and other 
animals (Underwood, 1977) i. f seems reasonable to su'ggest'that. the 
conversion of such a 'pro-RBP' into an active RBP molecule'might be 
a potential zinc-dependent regulatory step of RBP metabolism and 
hence of the mobilisation of'vitamin A. Studies on the mechanism 
of synthesis and secretion of RBP and the role of zinc in RBPI 
metabolism Might- provide an insight into the causation of altered 
vitamiu A metaboliSiTi inýsome cancer patients. 
Corticosteroids 
In addition, a study was conducted to explore the effects of 
exogenous corticosteroids on vitamin A status in rats. This study 
revealed that-high doses of corticosteroids, markedly depress 
vitamin A concentrations in the plasma, liver, adrenal glands and 
thymus. However, the effect of corticosteroids was greatest on the 
thymus, in which marked thymic shrinkage was accompanied by a rapid 
depl. etion of vitamin A. A similar effect was also seen in animals 
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subjected to stress (Seifter et al., 1976). Retinol (vitamin A) 
treatment concomitantly with corticosteroids had a profound effect 
on the thymus, for the vitamin A rose to values three' times hi'g'her 
than controls. The ability of the thymus to accumulate vitamin A 
in the presence of_corticosteroids suggests that there was an 
increased requirement for vitamin A. ' 
The thymus plays a key role in cell-mediafed immunity. The 
increased requirement for vitamin A in the thymus is suggestive of 
an antagonistic effect of vitamin A on the immunosuppressive effects 
of cortic0steroids. Seifter et al. (1978) have shown that 
vitamin A inhibits the growth of some immunogenic'tumour systems, 
and that this effect is related to the prevention of thymic 
I 
involution and/or proliferation that accompanies tumour growth. 
Thus, it is possible that low vitamip A might cause impaired 
immunoresponsiveness and decrease the ability of the host to deal 
with a small number of transformed cells (Rettura et al., 1976). 
It is of interest that several indices of immunocompetence are 
depressed in p3tients with cancer, and particiflarly in tfiose with 
lung cancer (Al-Saaraf et al., 1972; Wells et al., 1973; 
Brugarolas and Takita, 1973). In fact, stimulation of the immune 
response during therapy with retinyl palmitate or 13-cis retinoic 
acid has been reported in a study involving 9 male patients with 
metastatico unresectable, squamous cell carcinoma, who had not 
received previous treatment (Micksche et al.,, 1977). The authors 
suggested that there was some response to vitamin A therapy, but the 
results appear to be inconclusive. 
Chemotherapy 
It. was considered that the treatment, such as chemotherapy,, - 
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given to control malignant disease might well aggravate the 
abnormalities in vitamin A metabolism3, since antineoplastic agents 
are not selective with respect to malignant cells, but also damage 
cells with a high t. Urnover rate such as those of the gastro-intestinal 
tract. The combination chemotherapeutic regimens used in the 
treatment of metastatic testicular teratoma in this study have been- 
reported to cause nausea, vomiting, mucosal ulceration and damage to 
the gastro-intestinal tract (Ohnuma and Holland, 1977; Donaldson and 
Lenon, 1979). Thus, treatment with these drugs caused a marked 
fall in body weight plasma vitamin A and RBP, and to a lesser 
extent prealbumin. Treatment with these drugs also reduced the 
status of the patients with respect to other vitamins, includ ing 
vitamin E, thiamine and pyridoxine. 
In contrast to vitamin A, which is stored in the liver, thiamine 
and pyridoxine are not stored in appreciable amounts. in the body, and 
the maintenance of blood levels is therefore dependent*on normal 
dietary intake and absorption to a greater extent. It is noteworthy, 
that during treatment, the status with respect to the water-soluble 
vitamins either remained the same or-deteriorated still further. 
- 
In 
contrasts the plasma vitamin A, RBP and prealbumin concentrations 
rose to values higher than the pretreatment values at the start of 
the second. and subsequent courses of chemotherapy. A greater increase 
was observed with the carrier proteins. than with vitamin A. ' This - 
could possibly be due to-the reduction of some distant adverse effect 
of the neoplastic disease on the liver, for this organ plays a key 
role in the storage and mobilisation of vitamin A. Moreover, the 
elevation. of plasma vitamin A seemed to be of prognostic value, as 
the vitamin A status did not improve during treatment when the disease 
progressed. It is of interest that, Soukop and Calman (1978) have 
also suggested that the measurement of plasma vitamin A concentration 
/ 
207 
might be of prognostic value. 
The adverse effects of'the drugs used in our patients were 
not restricted to cancer patients, but were also observed in 
normal healthy experimental animals. Thus, treatment of healthy 
male rats with vinblastine and bleomycin, either singly, or in 
combination, in doses comparable to those of teratoma patients, 
resulted in a significant reduction in food intake and body weight 
gain and caused depletion of vitamin A from the plasma and the 
liver. The toxic effects of vinblastine administered singly, or 
in combination, were greater than those of bleomycin, and vinýlastine- 
treated animals had a dramatic loss in body weight. It is of 
considerable potential clinical importance that treatment with 
retinol (vitamin A), three hours prior to vinblastine administration 
markedly alleviated the toxic effects of the latter. Vitamin A- 
pretreatment caused a significant increase in food intake and 
curtailed the loss in body weight. . 'Furthermore, 
it also prevented 
the fall in the concentration of total protein and albumin in the 
plasma, and the fall -in the ccncent-ration of vitamin A in the plasma 
and liver. Thus, it seems reasonable to speculate that a similar 
b6neficial effect might be exerted in cancer patients if treated 
with these or other antineoplastic drugs. It would be of interest 
also to ascertain whether vitamin A has the potential to alleviate 
the adverse effects of radiation therapy too. 
However, the body's natural mechanism of averting vitamin A 
deficiency by storing excessive amounts in the liver confers a major 
potential limitation to vitamin A therapy. Thus, a dose response 
relationship was not observed on administration of high doses and 
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large amounts of vitamin A tended to be stored in the liver. 
Moreover, excessive amounts of retinoids in circulation cause' 
undesirable toxic side effects (Smith and Goodman, . 1976) although 
such effects were not observed in our study. It is of paramount 
importance thereforle, to determine whether synthetic retinoids 
that have the ability to prevent or arrest certain types of tumour 
growth have the potential to alleviate the toxic' effect of 
antineoplastic drugs. 
A notable example is 13-cis retinoic acid, which'has undergone 
extensive testing to evaluate its ability to arrest tumour promotion 
and progression (Sporn, 1977). This'compound has been-effective 
against a number of animal models which provide a spectrum of both 
transitional cell and squamous cell carcinoma of the bladder, which 
closely resemble the various stages of human disease (Sporn et al., 
1977; Squire et al., 1977; Grubbs et al., 1977). In fact, these 
studies have prompted the start of a trial for the pr evention of 
bladder cancer in disease-free patients who have undergone previous 
removal of at least two bladder carcinomas within six months prior 
to vitamin A therapy (Gunby, 1978). Several new synthetic analogues 
are now being evaluated in eiperimental studies (Sporn and Newton, 
1979). 
Recent studies. have revealed the presence of intracellular 
binding proteins, cellular retinol-and retinoic acid-binding proteins, 
which might act as' mediators of vitamin A action within the cell 
(Chytil and Ong, 1978; Chytil and Ong, 1979). The presence of these 
proteins could be an indication of whether the tumour responds to 
vitamin A therapy. The binding of retinoids to cellular binding 
proteins from experimental tumours correlated with their ability to 
209 
reverse metaplasias (Ong and Chytil , 1976; Chytil and. Ong, 1978). 
Some tumours may contain both proteins, while some contain n6ne 
or only cellular retinoic-acid binding protein (Chytil and Ong, 
1979). An interesting point was the observation of cellular reti. noic 
acid-binding protei n in human lung and breast carcinomas, but nof 
in the adjacent histologically normal tissue (Ong et al., 1975). 
Furthermore, these. workers also observed a complete disappearance of 
cellular retinol-binding protein when compared to th e healthy portion 
of the lung. However, the precise implications of these 
observations is not clear at present. 
From the work'presented in this thesis it seems possible to 
suggest that vitamin A plays a key role in carcinogenesis and. in 
the treatment of cancer. Deficiency of this vitamin caused by a 
number of factors (Fig. 6.2), would tend to increase the incidence 
of spontaneous, carcinogen- or virus-induced epithelial metaplasias 
and tumours by virtue of effects on cell differentiation, on the 
metabolism of potential carcinogens, on susceptibility to carcinogens 
and also on imm,, lnocompetence. Consequent growth of a tumour would 
then cause systemic changes in the host which would further depress 
the vitamin A status. For example, as observed in patients with 
lung cancer, an increased requirement for zinc during growth of the 
tumour might cause zinc deficiency and in turn affect the mobilisation 
of vitamin A. Or, as in patients with. metastatic testicular teratoma, 
impaired mobilisation of vitamin A might be a mainifestation of a 
distant effect of'the tumour on the liver. These deficiencies could 
be exacerbated by treatment such as chemotherapy and possibly 
radiotherapy. Moreover, low vitamin A status could increase the 
risk of infection and further complicate the disease process. Thus, 
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a deficiency of vitamin A might well be the key to a vicious circle 
(Fig. 6.2) affecting tumour incidence and growth and well-being 
of the host. 
The interacti; n of vitamin A deficiency with tumour growth i'n 
a vicious circle could be interrupted to some extent by giving 
vitamin A or synthetic retinoids. Studies on cancer patients-and 
follow up studies on experimental animals seem to suggest that 
treatment with vitamin A might enhance the body's natural defence 
mechanism and prevent the genesis or spread of the disease, particularly 
in patients with primary lung cancer. It may also alleviate. the 
devastating effects of chemotherapy in disseminated malignant disease 
such as testicular teratoma. These studies have clearly demonstrated 
the potential role of a single nutrient in relation to both the genesis and 
progreýs of a parti cul ar tumour, such as I ung cancer and of i ts 
potential as an adjuvant to the treatment of tumours. 
e 
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